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1
Hydatidiform mole
Epidemiology and clinical presentation
Gestational trophoblastic disease (GTD) includes a series of disorders that are 
characterized by an abnormal proliferation of trophoblastic tissue with varying tendency 
to spontaneous remission, local invasion and metastasis. Hydatidiform moles (HM) 
represent aberrantly formed placentas with abnormalities that are related to the villous 
trophoblast. Although complete and partial HM are benign, they may progress into 
malignancies. Gestational trophoblastic neoplasia (GTN) is the universal term for the 
wide range of malignant trophoblastic diseases comprising invasive mole, 
choriocarcinoma, epithelioid trophoblastic tumour and placental site trophoblastic 
tumour (PSTT) [1,2]. All tumour types may metastasize and are potentially fatal if 
untreated. Although GTN develops most commonly after a molar pregnancy, it may 
follow any type of gestation. The term persistent trophoblastic disease (PTD) is more 
specific, since it refers to GTN following a hydatidiform mole pregnancy. 
Hydatidiform mole pregnancies have the highest incidence of all forms of GTD [3-5]. 
They occur in approximately 1 in 1000 pregnancies, although there are geographic 
differences in incidence. While incidence rates in population-based studies in Europe, 
Oceania and the United States of America are fairly comparable, ranging between 0.6 
and 1.1 per 1000 pregnancies, Asia has been known to have incidence rates ranging 
from 0.8 to 3.0 HM per 1000 pregnancies [3]. Complete and partial HM have been 
recognized as separate entities since 1976 [6,7]. They are distinct in terms of 
epidemiology, clinical presentation, histopathology, genetics, epidemiology and the 
risk of developing GTN [8]. Due to detection of molar pregnancy at much earlier 
gestational age, the clinical presentation of complete HM has changed. Classically, 
HM was diagnosed in the second trimester of pregnancy. Patients would present with 
vaginal bleeding, anaemia, increased uterine size for dates, prominent theca lutein 
cysts, preeclampsia, hyperemesis gravidarum, hyperthyroidism and pulmonary 
trophoblastic emboli, associated with remarkably elevated hCG levels [9-11]. Today, 
most complete molar pregnancies are diagnosed in the first trimester of pregnancy, 
and the classical signs and symptoms are significantly less often present at time of 
diagnosis [12]. The clinical presentation of partial HM is less marked, with fewer clinical 
symptoms than complete moles. In general, patients with a partial molar pregnancy 
present with signs and symptoms of a missed or incomplete abortion [8,13]. 
Pre-evacuation hCG levels are usually lower in women having a partial mole compared 
to those having a complete molar pregnancy [8,14]. 
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Complete molar pregnancy is generally diagnosed by ultrasound, since they produce 
a characteristic vesicular ultrasonographic pattern in the absence of an identifiable 
fetus. This snow storm appearance can be seen on ultrasound even before vaginal 
spotting or the passage of vesicles [8,15]. However, it can be difficult to distinguish an 
early mole from non-molar degenerating villi by ultrasonography [15]. The ultrasound 
pattern in partial HM is less consistent and depends on careful measurement of the 
gestational sac and detection of cystic changes in the placenta. 
Histopathology
The golden standard for diagnosis of HM is histopathological examination of the 
material derived from uterine curettage. Classically, complete molar pregnancies 
present as a rapidly progressing total hydatidiform enlargement of villi with widespread 
gross trophoblastic hyperplasia in the absence of embryonic or fetal tissues (except in 
case of a twin pregnancy with a normal fetus) [16,17]. Fetal stromal blood vessels are 
usually absent, although Paradinas et al. noted that hydrops increased and vascularity 
decreased with gestational age [8]. A partial mole evacuated in the second trimester 
of pregnancy shows hydatidiform villi with mild trophoblastic hyperplasia next to normal 
chorionic villi. Stromal capillaries are often present and may contain erythroblasts. 
Embryonal structures may be found in partial moles [16,18]. In the first trimester those 
features may be more subtle [19]. Flowcytometry can be useful to differentiate between 
complete and partial moles as it describes the ploidy of the molar tissue [8,16,20]. 
Complete hydatidiform moles commonly have a diploid karyotype (46,XX, occasionally 
46,XY), representing reduplication of the haploid genome of the sperm in an enucleated 
oocyte or the fusion of two sperms with an enucleated oocyte. Partial HM are generally 
triploid (69,XXX or 69,XXY). This results from fertilization of a normal ovum by one 
sperm followed by reduplication of the haploid paternal genome, or from dispermic 
fertilization [16,21]. Diploid moles are generally androgenetic with two identical 
(homozygous) or different sets of paternal chromosomes (heterozygous) [22,23] and 
only seldom a biparental genome is observed [14,24]. Triploid moles have a biparental 
origin, with one maternal set and two paternal sets of chromosomes [8]. Flowcytometry 
may not be helpful in distinguishing between complete mole and hydropic abortions, 
as both complete mole and hydropic abortions are usually diploid. Immunohistochem-
ical analysis for expression of an imprinted gene, p57kip, can reliably differentiate 
complete moles and its mimics, since complete moles are generally negative for p57 
due to lack of a maternal allele [25].
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Prophylactic chemotherapy
The use of prophylactic chemotherapy administered shortly after molar evacuation has 
been studied in an attempt to reduce the incidence of post-molar PTD [26-28]. In a 
prospective randomized trial, 4 out of 39 (10.3%) patients developed PTD after one 
course of prophylactic methotrexate (MTX) in comparison with 10 out of 32 (31.3%) in 
the untreated group [26]. This difference was observed in particular in the group at 
increased risk of PTD (as defined by hCG levels > 100.000 IU/L, uterine size 
large-for-date and ovarian size more than 6 cm). However, in the PTD patients who 
received prophylactic chemotherapy and developed PTD afterwards, more courses of 
chemotherapy were required to gain disease remission than in patients that were not 
exposed to prophylactic chemotherapy. In another randomized trial, one course of 
Actinomycin D reduced the percentage of patients with malignant sequelae from 50% 
to 14% [27]. In both studies, no deaths occurred in the treatment or control groups due 
to GTD or toxicity. Moreover, prophylactic chemotherapy does not eliminate the need 
for hCG follow-up after molar evacuation [26,27]. In a large non-randomized study, 
7.5% of 293 HM patients prospectively treated with prophylactic MTX chemotherapy 
developed PTD, while significantly more patients (18.1% out of 127) developed PTD in 
the control group. The incidence in metastatic spread, however, was not statistically 
different among both groups [28]. Administration of prophylactic chemotherapy 
remains controversial; the main limitation is that a large proportion of HM patients 
receive needless chemotherapy with associated toxicity.
Human chorionic gonadotropin
HCG in pregnancy and gestational trophoblastic disease
HCG is a heterogeneous molecule produced by the syncytiotrophoblasts of the placenta 
and is generally known for its secretion during pregnancy. The intact molecule of hCG 
consists of a non-covalently bound α- and β-subunit. The α-subunit comprises 92 amino 
acids (hCGα) and is similar for other glycoproteins (LH, FSH, TSH). The β-subunit (hCGβ) 
consists of 145 amino acids and determines the biologic specificity of hCG. The molecular 
weight of intact hCG is approximately 37,500, of hCGα 14,000 and of hCGβ 23,500 Da. 
The α-subunit is transcribed from a single gene on chromosome 6 and is expressed in 
both pituitary and placental tissue [29]. The β-subunit of hCG is encoded by six different 
genes on chromosome 19 (β1, β2, β3, β5, β7 and β8). Beside intact hCG other forms of 
hCG may be present in serum such as nicked hCG, free β-subunit, nicked free β-subunit, 
β-subunit without C-terminal peptide and β-core fragment. The main physiologic function 
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of hCG is to maintain progesterone production by the corpus luteum in early pregnancy 
that represses maturation of other follicles, thereby assuring the sustainability of the 
endometrial wall for embryo implantation and continuation of pregnancy. HCG starts to 
increase in human maternal blood approximately 8 days after ovulation [30]. This 
increase in hCG levels is exponential, with 1.5 days of doubling time in the first 6 weeks 
of pregnancy [31]. Serum hCG peaks around 100,000 IU/L at 8-10 weeks after the last 
menstrual period. After the 12th week of gestation, hCG levels start to decrease, where 
after they plateau at approximately 30,000 IU/L from 20 weeks of pregnancy until term 
[56]. Following pregnancy, hCGβ levels showed a slower decline than intact hCG levels 
and therefore hCGβ  / hCG intact ratios vary with postpartum time [32]. Free α- and 
β-subunits have different secretion profiles during pregnancy. The levels of β-subunit in 
blood decline after the first trimester of pregnancy. The percentage of hCGβ as part of 
the total hCG immuno reactivity declines after 8 weeks of gestation to less than 1%. Free 
α-subunits on the other hand, continue to rise up to 30-40% of the total immuno reactivity 
of all hCG forms in the third trimester. The biological significance of secretion of hCG and 
its subunits during pregnancy remains to be elucidated [33]. All forms of gestational 
trophoblastic disease produce high levels of hCG, except for PSTT. Beside measurement 
of hCG in blood, hCG concentrations can also be measured in urine [34]. Serial hCG 
measurements have been used for a long time as an indicator for following the process 
of trophoblastic disease, reassuring sustained remission, checking the effectiveness of 
treatment and recognizing relapse and malignant transformation of molar pregnancies 
[35-37]. Assays that detect both hCG and hCGβ are mostly used for monitoring HM 
[35-37]. 
Glycosylation forms of hCG 
Glycosylation is an important posttranslational modification process in proteins, and 
aberrant glycosylation occurs in malignancies [38,39]. HCG is heavily glycosylated 
with eight carbohydrate chains. Two N-linked carbohydrate chains are attached to the 
hCG α-subunit and two N-linked and four O-linked sugar side chains are attached to 
hCGβ, contributing to approximately one-third of the molecular weight of hCG. HCG in 
blood of normal and molar pregnancy shows only limited proportions of more complex 
triantennary N-linked oligosaccharides (0-30%) and larger hexasaccharide-type-O-
linked carbohydrates (0-20%), while serum hCG in choriocarcinoma amounts up to 
100% of these larger N- and O-linked oligosaccharides. Glycosylation is of structural 
and functional importance, since both circulating half-life and signal-transduction of 
proteins is influenced by glycosylation [39]. The presence of terminal sialic acid (and/
or sulphate) attached to the carbohydrate side chains of glycoproteins causes a longer 
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passage time in blood and appears crucial for the biological action of these hormones 
[40].The carbohydrate structure of hCGβ obtained during normal pregnancy differs 
from that of malignant tumours [38,39,41], and large differences in glycan structures 
between the different glycosylation sites have been observed [39]. These glycoforms, 
called ‘hyperglycosylated hCG’ have been reported to contain more complex glycan 
structures. Hyperglycosylated hCG, produced by the cytotrophoblast, promotes 
invasion in both malignancy and normal pregnancy (unlike ‘normal’ hCG) and a lower 
proportion of hyperglycosylated hCG is related to early pregnancy loss. Variation in the 
N-glycan and O-glycan oligosaccharide structures of hCG results from differences in 
cellular metabolism and different expression of glycosyltransferase activities [41]. 
There are two main types of O-linked oligosaccharides called monoantennary and 
biantennary oligosaccharides. Elliott et al. showed that four O-linked oligosaccharides 
are the main difference between hCG produced by malignancies (choriocarcinoma 
and testicular germ cell tumour) and normal pregnancy hCG since choriocarcinoma-
derived urinary hCG contained more larger O-linked biantennary structures than normal 
pregnancy hCG [38]. Those differences were less obvious for the 4 N-linked 
oligosaccharide structures. N-linked biantennary oligosaccharides predominate at the 
two sites on the β-subunit of hCG in first trimester of normal pregnancy, while larger 
N-linked triantennary glycans prevail in choriocarcinoma. On the β-subunit of hCG, 
mono- and biantennary structures predominate in normal pregnancy, while tri-antennary 
N-linked structures predominate in choriocarcinoma patients [38,41]. Dissimilarities 
have also been observed in the sialic acid (which influences the pI level) and fucose 
contents of hCG between normal pregnancy and choriocarcinoma [38,39,41]. 
Especially mass spectrometry provides important structural information on glycoproteins 
[43]. In 2006, Valmu et al. showed the first site-by-site analysis of hCG oligosaccha-
rides using mass spectrometry by exploring multiple regular hCG and hyperglyco-
sylated hCG preparations from pregnancy, choriocarcinoma and testicular germ cell 
malignancies [39]. They found that site-specific differences existed in O-linked oli-
gosaccharides on the Ser 127, Ser 132 and Ser 138 in normal pregnancy (mainly 
mono-antennary) and choriocarcinoma (mainly bi-antennary). 
Measurement of hCG  
More than 50 years ago, the first bioassay was developed to diagnose pregnancy. 
Thereafter, radioimmunoassays (RIAs) were developed based on serum antibodies 
directed against intact hCG. However, this type of RIA was associated with low specificity 
for hCG due to high cross-reactivity with luteinizing hormone. Since then, more sensitive 
and specific RIAs were developed. In 1972, Vaitukaitis et al. were the first to develop a 
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RIA using polyclonal antibodies directed specifically against the β-hCG subunit of hCG 
[44].  Because this RIA was based on polyclonal antibodies directed against the 
hCGβ-subunit, it was called hCGβ RIA, although it should be realized that this assay 
measures both intact hCG besides the hCGβ-subunit. Therefore it would have been 
more appropriate to call this assay a hCG+hCGβ RIA. The hCGβ RIA discriminates 
between hCG and LH and detects all forms of hCG including intact, nicked, free β-subunit, 
β-subunit without C-terminal peptide and β-core fragment. Although some centers 
continued the use of a RIA, most laboratories use mono-, oligo- or polyclonal based 
double-determinant sandwich-type assays, since this type of assay can be performed 
automatically and is thus less labour-intensive, with a high throughput of samples. 
Sandwich assays use one or more antibodies to immobilize the hCG analyte (capture 
antibody) while a second labeled antibody binds on different sites of the immobilized 
hCG molecule to give a measurable concentration of the analyte, the tracer antibody 
[45]. Sandwich-type assays can be directed against a variety of epitopes on the hCG 
molecule. Due to the extensive possibilities of epitope combinations on the hCG 
molecule, a large number of hCG assays are available, with different specificity for hCG 
and the various subunits. Moreover, due to this variation in specificity, different hCG 
assay results are not always readily comparable. Sandwich-type assays are highly 
specific and some detect intact hCG only, while others detect all major forms of hCG. 
However, in patients with GTD, the major form of hCG present in blood, might be the 
other forms of hCG than the intact hCG molecule. Failure to detect these variants may 
result in failure to detect active trophoblastic disease. Therefore it is essential to use an 
hCG assay that detects all forms of hCG [46]. Rarely, hCG assays may lead to 
false-positive results as a consequence of heterophilic antibodies. Heterophilic antibodies 
are antibodies present in serum specimens against immunoglobulins of other species 
that are used in sandwich-type assays. These heterophilic antibodies bridges the capture 
and the tracer antibodies of the sandwich-type assay for hCG which may lead to 
false-positive hCG results. False-positive hCG results should be suspected if hCG levels 
plateau at low concentrations and do not respond to chemotherapeutic treatment. 
Since these heterophilic antibodies are not excreted in urine, urinary measurement of 
hCG can identify false-positive hCG results to prevent further unnecessary treatment for 
presumed PTD [47,48]. Furthermore, the presence of heterophilic antibodies causing 
false-positive test results can be identified and quantified by affinity chromatography, 
which is a labour-intensive procedure [49]. Sometimes persistent low hCG levels are 
present which are not caused by heterophilic antibodies and without clinical evidence for 
pregnancy or GTD [50]. This phenomenon is also called quiescent GTD and because 
these women do not respond to chemotherapy, treatment should probably be withheld 
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until the diagnosis of PTD is made according to the International Federation of 
Gynecology and Obstetrics (FIGO) 2000 criteria or clinically detectable disease is 
present. Continued surveillance is essential for those women, since they are at 
increased risk of developing PTD [50].
Persistent trophoblastic disease
Recurrent GTD following spontaneous remission
In uncomplicated cases, hCG levels become normal earlier in partial HM than in 
complete HM, on average 9 versus 11-14 weeks after evacuation of the molar tissue, 
respectively [8,51]. The appropriate length of the follow-up period has not been clearly 
defined. In general it is recommended that after evacuation of a complete or a partial 
mole, hCG levels should be monitored weekly until they become below normal cut-off 
level, followed by monthly monitoring for 6 months [52-54]. Effective contraception is 
indicated during the entire follow-up period in patients who have not undergone 
hysterectomy. Although current recommendations for hCG follow-up are meant to 
assure remission and to detect all relapse of GTD, hCG follow-up also causes anxiety 
and stress, delays childbearing in patients wishing to conceive and has a poor 
compliance [55-58]. Once patients achieve normal hCG levels, the risk of developing 
PTD is extremely low. Due to the relative low incidence of the disease, large recent 
studies on the risk of relapse of GTD following spontaneous normalisation of hCG 
levels are lacking. In one study from 1986, relapse of GTD was found in 1 out of 96 
patients after spontaneous normalisation of hCG levels [59]. This occurred only in 
those patients who failed to attain normal hCG values within 2 months after evacuation, 
while patients who achieved normal hCG levels within 2 months post-evacuation did 
not develop relapse of trophoblastic disease. In that study values of less than 25 IU/L 
in urine or 5 IU/L in serum were regarded normal. HCG tests used nowadays are much 
more sensitive. Other studies reported no evidence of PTD after spontaneous 
normalisation of hCG values after molar evacuation. In a study among 347 women 
none of the patients who once achieved undetectable levels of hCG developed 
malignant trophoblastic disease [9]. This study was performed in 1975, even before 
the advent of sensitive hCG assays. Lurain et al. followed 596 patients with spontaneous 
regression of trophoblastic disease and none of them had recurrence of GTD after 
normalisation of their hCG level [60]. Bagshawe et al. found in 1973 that none of the 
458 women with HM (not specified in complete and partial mole) developed recurrent 
trophoblastic disease once they achieved normal hCG levels [61]. In two recent 
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studies, none of the 150 patients and 400 patients, respectively, who achieved at least 
one serum hCG level below the normal hCG cut-off level had any evidence of relapse 
of GTD [57,62]. Wolfberg et al. found that among 876 patients, two patients had PTD 
diagnosed after their hCG level fell to less than the assay could measure. Both of these 
cases occurred in 1975, when the hCG assays used had a sensitivity of less than 10 
IU/L [63]. In a study from the Trophoblastic Disease Centre at Charing Cross Hospital 
in London only 3 out of 6279 (0.05%) patients whose hCG concentrations spontaneously 
returned to normal levels subsequently developed PTD (after 67, 402 and 1267 days, 
respectively). Two of those women achieved hCG normalisation within and one after 
more than two months post-evacuation [64]. After spontaneous normalisation of hCG 
levels, partial moles do not seem to develop recurrent trophoblastic disease [65-69]. 
Once more studies on the risk of relapse of GTD following spontaneous normalisation 
of hCG levels are available, the duration of the hCG follow-up can be re-evaluated.
Prediction of PTD
No generally accepted biochemical markers for prediction of PTD are available. Several 
investigators have studied the value of different biomarkers (progesterone, inhibin A, 
activin A, human placental lactogen, CA-125, carcinoembryonic antigen, CA 15-3, CA 
19-9, leptin, 17 β-estradiol) for early prediction of PTD [70-75]. However, these 
biomarkers in blood did not show clinical benefit for prediction of PTD. Measurement 
of hCGβ-subunit, nicked hCG, hCGβ core fragment, hyperglycosylated hCG and intact 
hCG also did not facilitate early prediction of PTD [73]. Several studies reported on the 
(retrospective) prediction of PTD in a pre-evacuation blood sample by means of 
measurement of hCG(-subunits). A retrospective study from our group has shown that 
hCGα, hCGβ and hCG+hCGβ concentrations are significantly elevated in blood of 
patients who will develop PTD compared with patients with spontaneous regression 
after evacuation of their moles. In predicting PTD, these analytes and parameters are 
moderately accurate tests [75]. Previously, other authors found an increased ratio of 
hCGβ to hCG+hCGβ in pre-evacuation blood samples of patients who eventually 
developed PTD compared with patients who achieved spontaneous remission [71,76]. 
A rising hCGβ to hCG+hCGβ ratio indicates a higher grade of malignancy while a rise 
in the proportion of hCGβ predicts the development of therapy resistance in patients 
receiving chemotherapy for PTD [77,78]. A retrospective study performed by Van 
Trommel et al. has shown that pre-evacuation blood hCGα, hCGβ and hCG+hCGβ 
concentrations are significantly elevated in patients who will develop PTD compared 
with patients with spontaneous regression after evacuation of their moles [79]. 
Unfortunately, in predicting PTD these analytes and parameters showed only moderate 
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diagnostic accuracy. Hyperglycosylated hCG has shown to be a sensitive marker for 
PTD prediction in post-evacuation blood samples In almost 50% of cases PTD was 
identified earlier by hyperglycosylated hCG than by the FIGO 2000 criteria [80]. In 
contrast to the previous findings on hyperglycosylated hCG in post-evacuation blood 
samples [81], Duc et al. found that hyperglycosylated hCG was not effective in the 
prediction of PTD prior to evacuation [82]. The diagnostic accuracy was moderate and 
not different from that of free hCGβ and hCG+hCGβ. 
Treatment modalities and staging
The FIGO 2000 criteria to diagnose PTD include 1) a plateau of hCG that lasts for four 
measurements over a period of at least 3 weeks: days 1, 7, 14 and 21, or 2) a rise of 
hCG of 10% or more for 3 values over at least 2 weeks: days 1, 7 and 14, or 3) 
persistence of hCG 6 months after mole evacuation or 4) the presence of an histological 
diagnosis of choriocarcinoma [83]. PTD occurs most commonly after evacuation of a 
complete HM, in approximately 15% of cases, although partial moles may also give 
rise to PTD (0.5%) [78,84]. Several authors described ‘normal’ serum hCG regression 
curves based on spontaneously declining hCG levels after molar evacuation for 
objective identification of PTD. These regression curves were based on serial hCG 
measurements among uneventful HM patients. Some authors found that hCG 
regression curves allowed significantly earlier identification of PTD than the FIGO 2000 
guidelines [84-87]. A normal regression curve can be used as an aid in the early 
detection of post-molar trophoblastic disease. A study performed in The Netherlands 
showed that false-positive diagnosis of PTD can be diminished by use of hCG 
regression curves, since 15% of uneventful HM patients exhibit a temporary plateau or 
rise in their hCG levels [85]. The Dutch criteria for persistent disease include a rise or 
plateau of hCG levels in 3 subsequent weekly measurements and at least one value 
exceeding the 95th percentile of the normal hCG regression curve [68,85]. To diagnose 
PTD, pregnancy has to be excluded [69-71]. The current FIGO criteria to diagnose PTD 
do not include metastatic disease. However, most centres would treat patients if a 
diagnosis of metastasis was made during post-molar follow-up, in particular brain, liver 
or gastrointestinal metastasis or radiologic opacities >2 cm on chest x-ray [88]. 
Patients suffering from PTD can be divided in a low and a high risk category depending 
on their prognostic risk score (Table 2). Patients are considered to have a high risk of 
chemotherapy-resistant disease if their cumulative prognostic score is 7 or more, while 
risk scores of 6 or less are considered low-risk [83].
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At present, single-agent chemotherapy is the treatment of choice for patients in the 
low-risk category (cumulative FIGO 2000 score 6 or less). Hysterectomy, in addition to 
chemotherapy, remains a treatment option for older patients not wishing to preserve 
fertility, since it may decrease the amount of courses required to achieve remission 
[89]. No large randomized controlled prospective trials have been performed to 
compare the efficacy of methotrexate and Actinomycin D and there is no consensus 
chapter 1
Table 1  Anatomic FIGO staging system for gestational trophoblastic 
disease
Table 2  Scoring system of the FIGO 2000 staging of trophoblastic  
neoplasia
Stage I Disease confined to the uterus
Stage II Disease outside of the uterus, limited to the genital structures
Stage III  Disease extends to the lungs with or without known genital tract 
 involvement
Stage IV All other metastatic sites
From: FIGO staging for gestational trophoblastic neoplasia 2000 
FIGO SCORE 0 1 2 4
Age ≤ 40 > 40 - -
Antecedent pregnancy Mole Abortion Term -
Interval months from index pregnancy < 4 4-7 7-13 ≥ 13
Pretreatment hCG mIU/mL < 103 103-104  104-105 ≥ 105
Largest tumour size including uterus - 3-5 cm ≥ 5cm -
Site of metastases Lung Spleen Gastro- Brain
  Kidney Intestinal Liver
Number of metastases identified 0 1-4 5-8 > 8
Previous failed chemotherapy - - Single- > 1
   agent
From: FIGO staging for gestational trophoblastic neoplasia 2000 
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regarding the treatment of choice. Low-dose MTX with folinic acid rescue is the most 
commonly used regimen for low-risk PTD and in general at least 2 consolidation 
courses of chemotherapy should be given after the first normal hCG level [90]. The use 
of routine second curettage for PTD is not recommended, since it is only effective in a 
small proportion of patients [91-93]. Patients with high risk-scores (FIGO 2000 score 7 
or more) are more likely to have tumours that are resistant to single-agent chemotherapy 
and should therefore be treated with first-line combination chemotherapy. EMACO 
(etoposide, methotrexate, actinomycine D, cyclophosphamide, vincristine), first 
described by the Charing Cross group, has shown to be an effective treatment for 
high-risk PTD [94-96]. In the largest study up to now, the cumulative 5-year survival 
rate was 86% in 272 patients who received EMACO chemotherapy for high-risk 
trophoblastic tumours. Complete remission was achieved in 78% of patients, while 
17% developed drug resistance, of whom 70% achieved remission on further 
cisplatin-based chemotherapy and surgery [95]. Combination chemotherapy gives 
rise to several secondary tumours, particularly colon cancer and myeloid leukemia 
[97]. Furthermore, chemotherapy for persistent trophoblastic disease, especially 
combination chemotherapy, advances menopause by several years [98]. No 
randomized controlled trials have been performed to confirm the remission rate and 
toxicities associated with EMACO. 
Chemotherapy resistance and relapse of PTD 
Resistance to single-agent chemotherapy occurs in approximately 17 to 36 % of 
patients initially diagnosed with low-risk PTD [98-100]. McNeish et al. reported in 2002 
on MTX resistance percentages as high as 31% in 485 patients initially treated with 
MTX [99]. An additional 2% of patients have required treatment conversion due to 
methotrexate toxicity. Sixty-seven patients changed to Actinomycin D of whom 58 
(86%) achieved normal hCG levels, while nine (14%) patients required EMACO 
combination chemotherapy. Ninety-four patients changed directly to combination 
therapy and all but one attained hCG normalisation on EMACO [99]. To date, the most 
widely used marker for resistance to MTX is a plateau or rise in serum hCG levels 
[99-102]. A generally accepted criterion to diagnosis chemotherapy resistance 
however, is lacking. Rotmensch et al. designed a log-exponential regression curve with 
hCG levels of 19 patients successfully treated with MTX [102]. Van Trommel et al. 
established a serum hCG normogram, based on hCG levels of 79 patients with low-risk 
PTD, cured by MTX alone. Fifty percent of low-risk PTD patients not responding to MTX 
(N = 29) could be identified just before commencement of the fourth MTX course 
[104]. Although results of the latter study were promising, the number of patients 
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included in this study was too low to allow introduction of this method in routine clinical 
practice. Following remission in patients initially treated for low-risk PTD, recurrence 
rates of trophoblastic disease are approximately 3% [101]. High-risk disease is 
associated with subsequent recurrence rates of approximately 1-5% [99,102]. Most 
women with relapse after treatment for low-risk PTD received EMACO chemotherapy, 
while for relapse following high-risk EMACO chemotherapy EPEMA (etoposide, 
cisplatin etoposide, methotrexate, actinomycine D) chemotherapy was instituted in 
most cases. In a recent study none of the 35 patients who relapsed after low-risk 
disease died [105]. The 5-year survival for patients who relapsed after high-risk disease 
is comparable with that for those with initial diagnosis of high-risk PTD. In case of 
relapsed or chemo-refractory disease the following factors were associated with poor 
outcome: metastatic disease at relapse, previous high-risk treatment, previous 
non-pulmonary metastases, non-molar pregnancies and a slow hCG doubling time. 
It is important to detect those patients with relapse of trophoblastic disease after 
PTD. Therefore the risk of relapse and time to relapse in The Netherlands need to be 
evaluated.
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Objectives of the thesis
As described in the first chapter, human chorionic gonadotropin (hCG) is crucial to 
diagnose and monitor patients with gestational trophoblastic disease. Widespread use 
of routine first-trimester ultrasound has resulted in earlier diagnosis of hydatidiform 
moles (HM). In chapter 2 we investigate the influence of earlier diagnosis and 
subsequent molar evacuation on serum hCG regression in patients with HM with 
spontaneous disease remission. After spontaneous remission following evacuation of 
the molar tissue, blood hCG levels are intensively monitored for at least 6 months in 
order to detect possible disease recurrence. Although literature data suggest that the 
risk of post-molar development of persistent trophoblastic disease (PTD) is rather low, 
a six months period of hCG follow-up after spontaneous normalization is still common 
practice throughout the world. However, delaying desired pregnancy for six months is 
rather a burden for most of these women. In chapter 3 and 4 we explore the risk of 
relapse of trophoblastic disease following normalisation of blood hCG levels in two 
independent cohorts of patients. 
At present there are no biomarkers available to predict the development of PTD in HM. 
Early prediction of PTD would enable optimal counselling and treatment of the patient 
at a less advanced stage of disease. Ideally, chemotherapy would be started shortly 
after evacuation of the molar tissue in order to minimize the extent of the disease and 
to save time in patients wishing to conceive. In chapter 5 the predictive value of hCG 
glycoform patterns is assessed in pre-evacuation blood samples of patients with 
complete HM. In chapter 6 prediction of PTD is studied using pre- and post-evacuation 
serum hCG concentrations.
Widely accepted criteria for diagnosis of chemotherapy resistance are not available. 
However, it is desirable to predict resistance to single-agent chemotherapy in an early 
stage in order to diminish the total duration of treatment. In chapter 7 prediction of 
resistance to first-line methotrexate chemotherapy is investigated by determining hCG 
cut-off levels for normal hCG regression in patients receiving single-agent methotrexate 
chemotherapy.
The thesis will be concluded with a general discussion and summary.
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Abstract
Objectives: To estimate serum human chorionic gonadotropin (hCG) regression in 
uneventful complete hydatidiform moles before and after the introduction of routine 
first-trimester ultrasonography.
Methods: Gestational age, maternal age, preevacuation hCG concentrations, serum 
hCG regression, and hCG disappearance time among a recent group of 137 women 
with uneventful complete hydatidiform moles that were found between 1994 and 2006 
were evaluated retrospectively and compared with a historical cohort of 106 patients 
with complete moles that were found between 1977 and 1989.
Results: Gestational age, preevacuation hCG concentration and hCG disappearance 
time were significantly lower in the recent complete hydatidiform mole cohort compared 
with the historic series. Ninety-nine percent of the recent cohort achieved hCG 
normalization within 19 weeks after uterine evacuation compared with 25 weeks in the 
historic group.
Conclusion: Earlier serum hCG regression in the recent cohort of complete hydatidiform 
moles probably is a result of widely used first-trimester ultrasonography leading to 
detection and evacuation of complete moles at younger gestational ages, resulting in 
lower hCG levels at time of evacuation.
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Introduction
Hydatidiform moles have been diagnosed at younger gestational ages in the past 10 
years owing to the widespread use of routine first-trimester ultrasound detection and 
ultrasound investigation of threatened miscarriage [1,2]. Historically, hydatidiform 
moles presented in the second trimester of pregnancy, typically with symptoms of 
vaginal blood loss and increased uterine volume accompanied by theca lutein cysts 
and hyperemesis due to excessive human chorionic gonadotropin (hCG) levels in the 
blood. Seldom, patients were asymptomatic at time of presentation [3]. Nowadays, a 
high number of complete hydatidiform mole patients is diagnosed coincidentally at 
routine first-trimester ultrasound examination without any classical symptoms. Typical 
ultrasonographic features, such as a combination of hypo- and hyperechogenic areas, 
are also less clearly present in recent years. Partial moles are more difficult to diagnose 
ultrasonographically [2,4]. Human chorionic gonadotropin, produced by the 
trophoblast, is a measure for trophoblastic activity. Therefore, hCG follow-up after 
evacuation of a hydatidiform mole is essential for all patients to detect those requiring 
further treatment. The frequency of preevacuation hCG levels of 100,000 international 
units/L or more is higher in diploid (complete) than in triploid (partial) moles [5]. 
Moreover, the hCG β-subunit is synthesized more abundantly in complete hydatidiform 
mole than in partial mole. The cause of this difference remains to be elucidated [6,7]. 
According to the criteria of the International Federation of Gynecology and Obstetrics 
(FIGO), persistent trophoblastic disease is defined as 1) a plateau in serum hCG plus 
or minus 10% of the baseline for 3 consecutive weeks, 2) an increase in serum hCG 
level greater than 10% from the baseline for 2 weeks, or 3) persistence of detectable 
hCG levels for more than 6 months after evacuation [8]. In the majority of hydatidiform 
mole patients, remaining trophoblastic tissue resolves spontaneously after uterine 
evacuation. Persistent trophoblastic disease (PTD) occurs in approximately 15% of all 
complete molar pregnancies [9]. A report from The Netherlands, published in 1993, 
shows that 95% of complete hydatidiform mole patients achieved hCG normalization 
by 25 weeks after uterine evacuation of the molar tissue [10]. First trimester 
ultrasonography increasingly became part of basic Dutch prenatal care in the early 
1990s to affirm gestational age [11]. With diagnosis of complete hydatidiform mole at 
younger gestational ages, spontaneous serum hCG regression after evacuation may 
have changed, resulting in earlier normalization of serum hCG levels. The aim of the 
present study is to estimate serum hCG regression in uneventful complete hydatidiform 
mole before and after the introduction of routine ultrasonography in the first trimester 
of pregnancy.
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Materials and Methods
The Dutch Central Registry of Hydatidiform Mole was established at the Radboud 
University Nijmegen Medical Centre in 1977. This registry serves mainly as an 
epidemiological database and provides advice and a national hCG assay service to 
local gynecologists. From 1977 through 1989 and from 1994 through 2006, respectively, 
907 and 1,647 patients were registered at the Dutch Central Registry for Hydatidiform 
Mole. Routine first-trimester ultrasonography was introduced gradually in the early 1990s. 
To make a clear-cut differentiation between patients diagnosed in the years before and 
after the introduction of routine first-trimester ultrasonography, patients diagnosed 
between 1990 and 1994 were not included for further analysis. The following exclusion 
criteria were applied: histological diagnosis other than complete mole, PTD, recurrence 
of trophoblastic disease after normalization of hCG levels, hysterectomy after hydatidiform 
mole, and patients for whom fewer than three hCG measurements were performed at the 
Central Registry Laboratory. Persistent trophoblastic disease was defined as static or 
rising hCG levels for 2 consecutive weeks. The Dutch Society of Gynaecology and 
Obstetrics added an extra criterion to the criteria for PTD, i.e. at least one hCG level 
exceeding the normogram for hCG regression described by Yedema et al. [10,12]. One 
hundred six patients with uneventful complete hydatidiform mole who were registered 
from 1977 through 1989 fulfilled the inclusion criteria (historic cohort). One hundred 
thirty-seven patients with complete mole with uneventful hCG regression, all registered 
from 1994 through 2006, were eligible for analysis (recent cohort). Patients with a brief, 
temporary plateau or rise in the hCG regression curve beneath the 95th percentile line of 
the normal regression curve also were included, provided that they had not received 
chemotherapy and had not undergone hysterectomy or second curettage. Histopathologic 
criteria for the diagnosis of complete hydatidiform mole have been described recently 
[13]. In case of doubt, the histopathological diagnosis was reviewed centrally by a 
specialized pathologist, including flow cytometric analysis or immune-histochemistry 
(p57 Kip). Gestational age, maternal age, preevacuation hCG, and hCG disappearance 
times among the recent cohort of patients with complete mole were compared with those 
among the historic cohort. The study has been carried out in The Netherlands in 
accordance with the applicable rules concerning the review of research, ethics 
committees, and informed consent. Serum hCG was measured weekly until normal 
levels were obtained and then monthly for 6 months. All serum hCG measurements were 
performed by means of a sensitive and specific radioimmunoassay, developed at the 
Central Registry Laboratory, using a polyclonal antiserum that measures both intact hCG 
and free β-subunits (total hCG), as described previously [14]. From here on, total hCG 
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will be referred to as hCG. The assay has been calibrated against the Third International 
Standard for human Chorionic Gonadotropin for Immunoassay (World Health 
Organization, 75/537). The measuring range for the standard line of the assay was 1 to 
80 ng/mL (0.027 to 2.14 nmol/L, equivalent to 9.29 to 743 international units/L). The 
hCG+hCGβ radioimmunoassay has a cross-reactivity of 100% on a mol/mol basis with 
intact hCG and 1,000% with hCGβ. All test results were expressed in ng/mL. The 
analytical sensitivity of the assay is 1.0 ng/mL. The cutoff value for normal hCG levels 
was established at 2.0 ng/mL, representing the cutoff serum concentration for normal 
levels at 95% specificity as found in postmenopausal women and hypergonadotropic 
men. The within-assay and between assay coefficients of variation for means of 
duplicate measurements were at a level of 10 micrograms/L (equivalent to 0.267 
nmol/L or 93 international units/ L), 7.5% and 10.3%, respectively, and at a level of 56 
micrograms/L (equivalent to 1.50 nmol/L or 520 international units/L), 7.3% and 12%. 
For patients whose hCG titers fell progressively to undetectable levels, 95th, 50th, and 
5th percentile lines of hCG regression were developed from serial weekly hCG levels 
sorted by week after evacuation (cross-sectional). Subsequently, a curve-fitting 
algorithm for exponential decay was used. Statistical analyses were performed using 
the SPSS 14.0 statistical software package for Windows (SPSS Inc, Chicago, IL). 
Human chorionic gonadotropin disappearance time is defined as the time from uterine 
evacuation until the time of the first normal hCG level. Normality of distributions was 
explored by use of the Kolmogorov-Smirnov test and frequency-distribution histograms. 
Differences in parametrical data were calculated by two-tailed Student’s t-test. 
Nonparametrical data were assessed by two-tailed Mann-Whitney U test. Frequency 
distributions were compared by Pearson’s Chi square test and, in case of expected 
counts less than 5, by Fisher exact test. Longitudinal analysis of hCG regression curves 
was performed by repeated measures analysis of variance. P values of less than .05 
were considered statistically significant.
Results
From 1994 to 2006, 137 patients diagnosed with complete hydatidiform mole fulfilled 
the aforementioned inclusion criteria. For those patients, a total number of 1,402 hCG 
measurements was known. For the historic cohort of complete mole patients (n=106), 
1,097 hCG concentrations were known. The preevacuation serum hCG levels in 
patients of the recent cohort were lower than in the historical cohort (median 4,100 ng/
mL compared with 8,600 ng/mL, P<.001), as shown in Table 1. 
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Patients with complete hydatidiform mole among the recent cohort had a significantly 
higher mean maternal age than did those with complete moles in the historic cohort 
(mean 29.9 compared with 28.3 years, P<.001). The percentage of patients with 
maternal ages below 20 years of age was not significantly different (3% in the recent 
group compared with 5% in the historic group); for patients older than 40 years, no 
statistically significant difference was observed (4% in the recent group compared with 
5% in the historic cohort). Gestational ages were lower in the recent cohort of patients 
with complete mole when compared with the historical cohort (mean 11.7 compared 
with 13.8 weeks, P<.001). Significantly more patients underwent uterine evacuation 
within 14 weeks of conception in the recent group than in the historical cohort of 
patients with complete hydatidiform mole (82% compared with 59%, P<.001). 
Human chorionic gonadotropin disappearance times were lower in the recent cohort 
(median 7.4 compared with 10.0 weeks, P<.001) than in the historic cohort. After 
evacuation of the molar tissue, 95% of all patients with complete mole in the recent 
series achieved hCG disappearance within 14 weeks; 95% of the historic cohort 
attained normal levels at 16 weeks after evacuation (Table 2). Ninety-nine percent of all 
patients with complete hydatidiform mole in the recent and historic cohorts attained 
hCG normalization within 19 and 25 weeks, respectively. 
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Table 1  Clinical Features of Recent and Historic Cohorts of Complete 
Hydatidiform Moles
 Complete HM Complete HM
 1994 to 2006 1977 to 1989
Clinical features     Recent cohort Historic cohort p
Pre-evacuation hCG (ng/mL) n= 55 82
Median (range) 4100 (160 - 35000) 8600 (5 - 53600) 0.001*
Maternal age (years) n= 136 106
Mean (95% CI mean) 29.9 (28.9 - 30.9) 28.3 (27.0 – 29.5) 0.05 †
Gestational age (weeks) n= 108 92
Mean (95% CI mean) 11.7 (11.1 - 12.4) 13.8 (13.0 - 14.6) < 0.0001 †
HCG disappearance time 
(weeks) n= 130 97
Median (range) 7.4 (2.4 - 19.4) 10.0 (3.9 - 25.0) < 0.0001*
HM; hydatidiform mole, hCG; human chorionic gonadotropin,  
* Mann-Whitney U test, † Student’s t-test
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Figure 1 shows the 5th, 50th, and 95th percentile lines for normal regression of hCG 
levels after molar evacuation in the recent and historic cohorts. The three dashed lines 
correspond to the 5th, 50th, and 95th percentiles of uneventful regression of the recent 
earlier diagnosis and serum hcg regression in complete hm
1
10
100
1000
10000
100000
0 5 10 15 20 25
S
er
um
 h
C
G
+
hC
G
β 
(n
g
/m
L)
Weeks after evacuation 
Table 2  Cumulative percentage of patients with hCG normalisation among 
the recent and historic cohort of complete hydatidiform moles
Figure 1  5th, 50th and 95th percentile lines of serum hCG regression  
following evacuation of complete hydatidiform mole in the recent 
(dotted lines) and historical series (continuous lines)
Cumulative percentage 
of patients  
with hCG normalisation 1% 2.5% 5% 50% 95% 97.5% 99%
CHM 1994 - 2006 
(weeks after evacuation) 2 3 4 7 14 16 19
CHM 1977 - 1989
(weeks after evacuation) 4 5 6 10 16 20 25
CHM; complete hydatidiform mole, hCG; human chorionic gonadotropin
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group of patients with complete moles; the three continuous lines represent the 
percentile lines of the historic cohort. The horizontal broken line represents the cutoff 
serum concentration of hCG (2.0 ng/mL). 
Linear regression repeated measures analysis revealed that, for patients with complete 
serial consecutive hCG levels until week 9 after evacuation (n=31 for the recent cohort, 
n=50 for the historic cohort), between-subject effects were significantly different (P=.003). 
When comparing hCG levels per week after evacuation, regression of serum hCG in 
the recent group has shifted to the left because serum hCG levels among the recent 
group were significantly lower than in the historic series (Table 3).
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Table 3  Comparison of serum hCG levels per week after uterine evacuation 
in the recent and historical cohort of complete hydatidiform moles
  hCG (ng/mL)  hCG (ng/mL)
Weeks after    CHM 1994-2006  CHM 1977-1989 
evacuation  Median (range)  Median (range)
     p*  
 n =  n =
0 56 451 (5.2 -18000) 84 3750 (2.5 - 53600) < 0.0001
1 79 73 (4.0 - 2640) 63 170 (1.0 - 32000) < 0.0001
2 87 30 (1.0 -1300) 66 47 (2.7 - 1300) < 0.0001
3 90 15 (1.0 - 210) 71 25 (1.0 - 700)    0.001
4 97 5.1 (1.0 - 4900) 61 13 (1.6 - 1400) < 0.0001
5 89 4.0 (1.0 - 720) 60 8.6 (1.0 - 1500) < 0.0001
6 88 2.2 (1.0 - 182) 61 4.3 (1.0 - 1400)    0.001
7 79 2.1 (1.0 - 81) 51 2.8 (1.0 -1500)    0.006
8 70 1.1 (1.0 - 63) 49 2.4 (1.0 - 280) < 0.0001
9 64 1.2 (1.0 - 27) 52 2.0 (1.0 - 820)    0.002
CHM; complete hydatidiform mole, hCG; human chorionic gonadotropin, * Mann-Whitney U test
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Discussion
The aim of the present study was to estimate serum hCG regression in uneventful 
complete hydatidiform mole in The Netherlands before and after the introduction of 
routine first-trimester ultrasonography. Serum hCG disappearance advanced when 
comparing regression curves of patients with complete mole before and after the 
introduction of routine first trimester ultrasonography, which coincided with lower 
preevacuation hCG levels in the latter series. Ninety-nine percent of the recent cohort 
of patients with complete mole achieved hCG normalization within 19 weeks after 
uterine evacuation compared with 25 weeks in the historic group. As expected, 
gestational age at time of evacuation was significantly lower in the recent cohort of 
complete hydatidiform mole than in the historic group, and more patients underwent 
uterine evacuation within 14 weeks of conception. Because of the retrospective nature 
of the present study, hCG measurements on a weekly basis were not available for all 
patients. Ideally, a prospective cohort survey would have been performed, with hCG 
measurement at the Radboud University Nijmegen Medical Centre laboratory for all 
individual patients in all subsequent weeks, including a preevacuation hCG level. 
However, this was not feasible owing to the low incidence of complete hydatidiform 
mole. Uniformity in ultrasonographic diagnosis of complete mole might be distorted by 
interobserver variation because ultrasound examinations were performed in different 
hospitals (both academic and regional hospitals). Uniformity in hCG measurement, 
however, was achieved by hCG measurement at one central laboratory because 
absolute hCG levels measured by use of different assays are not comparable owing to 
differences in assay sensitivity and specificity. Complete hydatidiform moles terminated 
during the first trimester of pregnancy histologically resemble late partial moles, and 
early partial moles resemble hydropic abortion. It is not unlikely that misclassification 
occurred more often as a result of evacuation in the first trimester of pregnancy when 
compared with the moles evacuated later in pregnancy [13,15]. The increase over time 
in maternal age observed in patients with complete mole is in line with the rise in 
maternal age in the general pregnant population. In the Dutch population, the mean 
maternal age at time of birth of the first child was 25.6 years in 1980, which increased 
to 29.4 years in 2006.16 The decrease in gestational age at time of evacuation of 
complete mole in recent years also has been reported by other authors [1].
In 1993, Yedema et al reported on hCG normalization within 25 weeks after uterine 
evacuation in 95% of Dutch patients with complete hydatidiform mole [10]. A normogram 
for serum hCG regression was developed from the 95th percentile line of hCG regression 
earlier diagnosis and serum hcg regression in complete hm
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among 129 patients with uneventful complete hydatidiform mole. Until now, exceeding 
the serum hCG normogram is used as an additional criterion for diagnosis of PTD in 
The Netherlands [12]. Recurrence of trophoblastic disease after spontaneous 
normalization of serum hCG levels occurred rarely [17]. Ultrasonography has been a 
widely accepted, reliable method for the diagnosis of complete hydatidiform mole for 
several decades [18]. The clinical presentation in uneventful complete moles has 
changed in the past 30 years, most likely owing to ultrasound detection at younger 
gestational ages by the widespread use of routine first-trimester ultrasonography and 
ultrasound investigation of vaginal blood loss in threatened miscarriage [1,2,4]. 
Consequently, lower gestational age at time of evacuation caused lower preevacuation 
hCG levels and therefore shortened hCG disappearance times when compared with 
the historical cohort. Also, improved technology and increased experience in complete 
mole detection by early ultrasound examination might have contributed to this decrease 
in gestational age. Aside from the effect of younger gestational age at time of 
evacuation, other factors might have contributed to the reduction in hCG disappearance 
time after uneventful complete mole evacuation. For instance, it seems reasonable to 
assume that uterine curettage has become more complete in terms of evacuating 
trophoblastic tissue in recent years owing to the increased use of ultrasound guided 
curettage. Nevertheless, earlier evacuation of complete hydatidiform mole did not 
result in a significant decrease in the incidence of PTD [1]. In case this trend of earlier 
hCG disappearance in recent years also is observed in larger cohorts, the third FIGO 
criterion (ie, persistence of detectable hCG levels for more than 6 months after 
evacuation) might be outdated. However, the present findings alone do not justify 
modification of the third FIGO criterion because the number of patients diagnosed with 
PTD by this criterion is unknown. Presumably, this number is limited because no more 
than 10% of 86 patients with PTD were identified by the FIGO 2000 criteria more than 
11 weeks after evacuation [19]. Furthermore, the clinical relevance of diagnosis of PTD 
several weeks earlier remains to be investigated. In conclusion, serum hCG 
disappearance occurred significantly earlier in the recent cohort than in the historic 
cohort of patients with complete hydatidiform mole. This is most probably a result of 
widely used first-trimester ultrasonography leading to earlier diagnosis and evacuation 
of complete hydatidiform mole, resulting in lower hCG levels at time of evacuation.
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Abstract
Objectives: The aim of this study was to determine how often patients with complete 
hydatidiform mole (CHM) who spontaneously achieved normal human chorionic 
gonadotropin (hCG) levels subsequently developed persistent or recurrent gestational 
trophoblast disease. 
Methods: Four hundred and fourteen cases of CHM registered at the Hydatidiform 
Mole Registry of Victoria were reviewed retrospectively after molar evacuation. Maternal 
age, gestational age, gravidity and parity were determined for each patient, as well as 
the need for chemotherapy.
Results: Among the 414 patients, 55 (13.3%) required chemotherapy for persistent 
trophoblastic disease. None of the patients whose hCG levels spontaneously fell to 
normal subsequently developed persistent molar disease.
Conclusion: Weekly hCG measurements are recommended for all patients until normal 
levels are achieved. For patients who attain normal hCG levels within 2 months after 
evacuation, it seems safe to discontinue monitoring once normal levels are achieved. 
Patients who fail to achieve normal hCG levels by 2 months after evacuation should be 
monitored with monthly hCG measurements for 1 year after normalisation to assure 
sustained remission.
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Introduction
Complete hydatidiform moles (CHM) form a well-defined group at risk of development of 
malignant disease. Although current recommendations for human chorionic gonadotropin 
(hCG) follow-up are meant to assure remission and to detect all relapse of persistent 
trophoblastic disease, hCG follow-up is also resource intensive, causes anxiety and 
stress, delays child bearing, and is subject to significant non-compliance [1-4]. It appears 
that once a patient with complete molar pregnancy attains undetectable hCG levels, the 
risk of gestational trophoblastic tumour relapse is extremely low. Bagshawe et al. found 
in 1973 that none of the 458 women with hydatidiform mole (not specified whether 
complete or partial) developed recurrent trophoblastic disease once they achieved 
normal levels [5]. In 1986, however, Bagshawe found that one in 96 patients with CHM 
who failed to attain normal hCG values 2 months after evacuation developed trophoblastic 
disease after spontaneous normalisation. In that study, values of less than 25 IU/L in 
urine or 5 IU/L in serum were regarded as normal [6]. Other studies have reported no 
evidence of persistent trophoblastic disease (PTD) after spontaneous normalisation of 
hCG values after molar evacuation. In a study of 347 women, Curry et al. found that no 
patient who achieved undetectable levels of hCG developed malignant trophoblastic 
disease [7]. This study was performed in 1975, even before the advent of sensitive hCG 
assays. Lurain et al. followed up 596 patients with spontaneous regression of trophoblastic 
disease, none had recurrence of gestational trophoblastic disease (GTD) after 
normalisation of their hCG levels [8]. Recently, Batorfi and Feltmate reevaluated the 
length of the follow-up period after molar pregnancies. None of the 150 patients in 
Batorfi’s study and none of the 400 patients in Feltmate’s report who achieved at least 
one undetectable serum HCG level had any evidence of relapse or persistent trophoblastic 
disease [3,9]. Wolfberg et al. found that only two of 876 patients had persistent disease 
diagnosed after their hCG level fell to normal, both of these cases occurred in 1975, 
when the hCG assays used had a sensitivity of less than 10 mIU/mL [10]. Considering 
the extremely low risk of recurrence of GTD after normalisation of hCG, it is possible that 
the extent of hCG monitoring after normalisation of hCG may be shortened without 
compromising patients’ health and safety. No cases of tumour occurrence after initial 
normalisation have been reported in patients who achieved normal hCG values within 2 
months after curettage [3,6,9,10]. The current study was undertaken to review the 
experience with (urinary) hCG follow-up in patients with complete hydatidiform moles, 
particularly related to the risk of persistent disease after attaining normal levels and to the 
need for chemotherapeutic treatment if hCG levels failed to normalize by 2 months after 
evacuation of the molar tissue.
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Materials and methods
A central registry of cases of hydatidiform mole was established at the Royal Women’s 
Hospital, Melbourne, in September 1973. The Hydatidiform Mole Registry of Victoria 
provides a free, postal follow-up service for women with gestational trophoblastic 
disease. The aims of this registration are the collection of epidemiologic data on the 
incidence of Hydatidiform Mole in Victoria, the early detection of persistent trophoblastic 
disease, and to serve as a referral centre for other physicians. In patients in whom the 
diagnosis of a molar pregnancy is established, the uterus is evacuated by suction 
curettage. Recommended investigations following registration include a chest X-ray and 
serial 24-h urine collections for estimation of urine chorionic gonadotrophin levels or 
blood samples for the estimation of the beta-subunit of hCG. Following registration, 
patients are sent instructions and information about hydatidiform mole pregnancies and 
follow-up. Patients who fulfill the criteria for diagnosis of a CHM supply 24-h urine 
collections for estimation of urinary chorionic gonadotrophin (UCG) excretion at weekly 
intervals until levels return to normal and then monthly for 12 months. If the patient fails 
to complete the recommended hCG monitoring, a default letter is sent. All urinary hCG 
measurements were performed at the RWH laboratory and in some cases, serum hCG 
results were received from the referring hospital. Once levels have returned to normal 
and have remained so for 9 months, the patient is advised that she may attempt another 
pregnancy. During a subsequent pregnancy, no UCG measurements are performed, but 
this assay is requested 6 weeks after the pregnancy is completed. An early ultrasound 
is performed in all subsequent pregnancies, because of the increased risk of a second 
molar pregnancy. The placenta is examined for the presence of molar disease as well. 
Until 1998, patients diagnosed with a partial molar pregnancy were followed up for 6 
months after normalisation of UCG. Since then, those patients are no longer followed 
up, because of the very low risk of developing persistent trophoblastic disease. This 
approach is the subject of another report [11]. Patients who develop persistent disease 
are followed up for 1 or 5 years, for low-risk and high-risk categories, respectively. 
Patients suffering from a choriocarcinoma are followed up for 5 years after diagnosis, 
regardless of the presence of metastatic disease. Patients possibly requiring 
chemotherapy are admitted and treated under the care of the oncology unit of the Royal 
Women’s Hospital, although chemotherapy may be given at the referring centre. The 
scoring system used in Australia is that developed by the World Health Organization. 
The Gynaecological Group of the Clinical Oncology Society of Australia no longer 
recognises a medium-risk category in GTD, because of the low toxicity and high cure 
rates achieved with etoposide, methotrexate, actinomycin-D, cyclophosphamide, 
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oncovin (EMA/CO) chemotherapy. In practice, there are two groups of patients; those 
with biochemical disease following evacuation of a hydatidiform mole treated with 
methotrexate and folinic acid rescue and all others who are treated with EMA/CO. 
Patients with choriocarcinoma or metastatic disease after a molar pregnancy, or after an 
abortion or term pregnancy, are all treated with EMA/CO, except in the case of a single 
lung metastasis after a hydatidiform mole. Biochemically non-responders to low-risk 
treatment and those in whom low-risk treatment causes severe side-effects are also 
treated with EMA/CO. This study was based on the clinical records of all patients 
diagnosed with complete hydatidiform mole, registered from 1 January 1992 until 1 
January 2001. The clinical course of each patient following molar pregnancy was 
evaluated by reviewing the patient’s clinical file, relevant correspondence and hCG 
assay data. Data regarding these patients were extracted from the archives of the 
Hydatidiform Mole Register of Victoria, and transferred to a computerised database. The 
following features were determined from the medical records: pathological review 
diagnosis by the RWH pathologist, maternal age at diagnosis, obstetric history, 
gestational age, ABO and rhesus blood group, country of birth, evacuation method, 
history of previous mole, chest X-ray result, urinary and serum hCG follow-up data and 
chemotherapy. The pathological diagnosis is mostly based on histology, but ploidy 
studies and p57KIP2 were used in case of doubt. The criteria used have been described 
elsewhere [12,13]. Investigations included chest X-ray, ultrasound examination of the 
pelvis and 24-h urine collections for estimation of urine chorionic gonadotrophin levels 
and/or estimation in serum of the beta subunit of HCG. Radioimmunoassays were 
performed on 24-h urine collections, and during the last year of this study, the Immulite 
method was used [14]. The assays were sensitive enough to detect less than 2 IU/L. 
Values of less than 2.5 IU/L in urine and less than 2 IU/L in serum were regarded as 
normal. During this period, 843 patients (847 cases) were registered at the Hydatidiform 
Mole Registry of the state of Victoria, 433 cases fulfilled the criteria for diagnosis of a 
complete molar pregnancy on the review of the biopsy specimen by the specialised 
gynaecological pathologist. Table 1 shows the clinical diagnoses of the patients 
registered during the study period. Patients who were misdiagnosed as having 
gestational trophoblastic disease, patients with a partial molar pregnancy, tubal molar 
pregnancy, coexisting twin pregnancy, repeat molar pregnancy and those patients who 
were referred for treatment of existing malignant trophoblastic disease were excluded 
from this study. Also excluded were the patients for whom there was incomplete 
information regarding the pathological diagnosis. The remaining 414 patients diagnosed 
with a complete hydatidiform mole were selected for review. Patients with complete 
hydatidiform mole were considered to have entered spontaneous remission after 
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evacuation of the molar tissue when UCG assays indicated spontaneous decline of 
UCG to < 2.5 and UCG remained < 2.5 on multiple repeat assays during the next year 
and when the clinical course of the patient showed an absence of residual disease. A 
persistent plateau or rise in the UCG level indicates persistent trophoblastic disease and 
thus the need for chemotherapeutic treatment. The need for further treatment was based 
on the presence of any one or more of the following criteria: plateauing UCG levels for 
three or more consecutive weeks; rising serial UCG levels (two or more consecutive 
samples); the presence of metastases (except where a solitary pulmonary metastasis 
was present and UCG levels were falling); the presence of extensive myometrial invasion 
and intraperitoneal bleeding. Recurrence can be defined as the need for chemo-
therapeutic treatment after spontaneous normalisation of hCG levels after suction 
curettage of the molar tissue, in the absence of a subsequent pregnancy. Statistical 
analyses were performed by the use of the two-tailed Student’s t-test. Statistical 
significance was set at the 5% probability level. As this study conformed to the standards 
established by the NHMRC for ethical quality review, ethics approval was not sought [15].
Results
Histopathology
Table 1 summarizes the clinical diagnoses of patients registered at the Hydatidiform 
Mole Registry of Victoria, Australia, from 1992-2000. Among the 847 cases examined 
by the Royal Women’s Hospital pathologist, the review diagnosis was complete mole 
in 433 cases (including one patient with a complete mole and a coexisting partial mole 
and two patients with repeat molar pregnancy within the period of study). Partial molar 
pregnancy was diagnosed in 345 cases (including the aforementioned twin pregnancy 
and one patient with two molar pregnancies). Eleven cases were diagnosed as 
hydatidiform moles without further specification of the molar type. The review of 
histologic material of the 847 cases with an initial diagnosis of gestational trophoblastic 
disease, resulted in incomplete or hydropic abortion (misdiagnosed) in 43 cases, 
invasive mole based on ultrasound -without evidence of trophoblastic disease on 
pathological examination- in one case, exaggerated placental site reaction in two 
cases and ectopic tubal pregnancy in two cases. Ten cases were diagnosed as 
choriocarcinoma and PSTT as a primary diagnosis (without a known antecedent molar 
pregnancy or unclear molar type). From 1992-2000 843 patients were registered. The 
reason that the total number of patients diagnosed with gestational trophoblastic 
disease (GTD) and the total number of cases with GTD do not correspond, is that three 
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patients had repeat molar disease during the period of study and 1 patient had a 
complete hydatidiform mole with a coexisting partial twin pregnancy.
Incidence of complete hydatidiform moles 
No exact data on the number of home abortions could be determined, for that reason 
estimates of the incidence of complete hydatidiform mole and persistent disease are 
calculated against the number of live births in Victoria.
Table 2 summarizes the incidence of CHM compared to the number of live births in 
Victoria. Between the 1st of January 1992 and the 1st of January 2001 568,279 live births 
were registered in the State of Victoria [16-18]. Four hundred and thirty-three cases of 
complete molar pregnancy were registered, giving an incidence of 0.76 reported 
complete molar pregnancies per 1000 live births. The total incidence of hydatidiform 
mole was 1.37 per 1000 live births. 
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Table 1  Clinical diagnoses and chemotherapy status of cases registered 
at the Hydatidiform Mole Registry Victoria, 1992-2000 
Diagnosis     No. of cases Had 
   chemotherapy
Hydatidiform mole 778 63
 Complete hydatidiform mole (CHM) 432* 57
	 Partial	hydatidiform	mole	(PHM)	 344•	 6
 Twin pregnancy CHM with coexisting PHM  1 0
Gestational trophoblastic disease, 
not further specified 11 4
Misdiagnosed 48 3
Choriocarcinoma as primary diagnosis 8 8
Placental site trophoblastic tumor as 
primary diagnosis 2 1
Total 847 cases 79 cases
*		Including	two	patients	who	had	2	moles	(1992-2000)		•	Including	one	patient	who	had	2	moles	
(1992-2000)
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Table 2  Incidence of complete hydatidiform moles per 1000 live births in 
the state of Victoria 
Year Live births CHM* CHM/1000 Treated  Treated/1000
    live births CHM# live births
1992-2000 568,279 433 0.76 57 0.10
* Number of cases registered in the Hydatidiform Mole Registry of Victoria diagnosed with CHM
# Number of cases treated with chemotherapy for persistent trophoblastic disease
 Registered GTD
(n=847;chemo:79)
PHM
(n=345;chemo:6) 
CHM
(n=433;chemo:57)  
Other*
(n=69;chemo:16)
Ectopic
(n=1;chemo:0)
Twin#
(n=11;chemo:1) 
CHM
(n=414;chemo:55)
Repeat Mole
(n=7;chemo:1)
Chemotherapy
(n=55;13.3%)
No chemotherapy
(n=359;86.7%)
Chemo
< 2 months
(n=32)
Chemo
> 2 months
(n=20)
Chemo
date not
known
(n=3)
Normal
< 2 months
(n=144)
Normal
> 2 months
(n=114)
Normal
date not
known
(n=29)
Lost
to FU
before
normal
(n=72)
No
recurrence
No
recurrence
No
recurrence
Figure 1  Persistent Trophoblastic Disease after CHM
*  Gestational  trophoblastic disease, not further specified (n=11;chemo:4), Misdiagnosed 
(n=48;chemo:3),  Choriocarcinoma as primary diagnosis (n=8;chemo:8), Placental site  
tropho blastic tumor as primary diagnosis (n=2;chemo:1)
#  Twin: Including 10 patients with CHM and a coexisting normal twin (chemo:1) and 1 patient 
with CHM and a coexisting  PHM
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Cases of a twin pregnancy with a normal twin (n=10) and a partial hydatidiform mole 
twin (n=1), repeat molar pregnancy (n=7) and an ectopic pregnancy (n=1) were 
excluded for further analysis, for that they are at increased risk of developing persistent 
trophoblastic disease. The results below pertains to the remaining 414 patients.
Compliance
Compliance was evaluated for the uncomplicated cases among the 414 patients with 
‘normal’ CHM; women who received chemotherapy (n=55) were excluded for analysis 
of compliance. (Table 7) For the remaining 359 patients, the follow-up length was 
analysed.
Fifty-six patients (16%) completed follow-up (weekly measurements until normal levels 
and after attaining normal hCG levels monthly for 1 year) for CHM and 303 patients 
(84%) discontinued the follow up procedure before it had been completed. Two 
hundred and two patients (56%) were followed-up for at least 6 months after evacuation 
of a complete mole. Seventy-two women (20%) were lost to follow up before achieving 
normal hCG levels. Among those patients, 30 were lost before normalization -after the 
hCG concentration already reached hCG levels of less than 10 IU/L- 12 were lost to 
follow up before attaining hCG values of less than 10 IU/L and for 30 patients no hCG 
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Table 3  Compliance with hCG follow-up in patients with complete 
 hydatidiform mole (n=359) 
  No. of patients 
Normal hCG levels achieved  287 
Compliant for entire follow-up period*  56
Compliant for at least 6 months after normalization   202
Lost to follow-up before normal hCG levels  72
 Not one hCG assay performed  30
 Lost before normalization, hCG levels <10 IU/L  30
 Lost before normalization, hCG levels ≥10IU/L  12
Pregnant during follow-up period  31
*  Follow-up protocol: weekly measurements until normal hCG levels and then monthly for  
12 months 
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measurement was performed after evacuation of CHM. At least 31 women (9%) became 
pregnant during the recommended follow-up period.
Persistent trophoblastic disease
Among the 414 cases of ‘normal’ complete molar pregnancy referred for follow up to 
the Hydatidiform Mole Register of Victoria in the years 1992-2000, 55 cases (13.3%) 
required chemotherapeutic treatment for persistent trophoblastic disease (PTD). Figure 
1 describes the risk of persistent disease in patients who attained normal hCG levels 
within 2 months after evacuation and in patients who had not achieved normal hCG 
levels within 2 months after evacuation. Patients for whom the chemotherapy date 
could not be retrieved from their medical record (n=3) were excluded from this analysis, 
together with patients who failed to complete their follow-up procedure before they 
attained normal hCG levels (n=72). Women who started follow-up more than 2 months 
post-evacuation, and whose first assay was normal (n=29), were not included, because 
for those women it was not possible to determine whether they normalized before or 
after 8 weeks after evacuation. Among the patients with a known normalization or 
chemotherapy date (n=310), 43% (n=114+20) had elevated hCG titers at 2 months 
after evacuation. Of those 134 previously untreated patients 15% (n=20) subsequently 
required chemotherapy. Among the patients who attained normal hCG levels, the 
longest time for hCG to reach normal values was 44 weeks. Importantly, none of the 
287 patients who spontaneously declined to normal levels (including the patients who 
attained normal levels without a known normalization date) and had at least one normal 
hCG level, subsequently required chemotherapeutic treatment for persistent 
trophoblastic tumor. 
Maternal age
Maternal age was evaluated for 408 of the 414 patients with CHM. Six patients had no 
information regarding the date of evacuation in their medical record, these patients 
were excluded. The age of the remaining 408 patients ranged from 15 to 57 years with 
a median age of 29 years (Table 4). Women aged 15 to 19 years and women aged over 
40 years, especially those aged over 45, are at increased risk of a CHM pregnancy, 
compared to women aged 20 to 40 years. The mean maternal age at evacuation of 
patients with uncomplicated complete hydatidiform mole compared to the mean 
maternal age of patients with persistent CHM showed no statistically significant 
difference (29.3 compared to 29.9 years, P=0.5).   
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Gestational age
Gestational age (the number of days between the first day of the last menstrual period 
and the day of the termination of the pregnancy) was calculated for 371 of the 414 
patients diagnosed with CHM. Patients without information about the gestational age 
in their medical record were excluded (n=43). The gestational age ranged from 4 to 41 
weeks, with a median gestational age of 10 weeks (Table 5).
The highest proportion of patients needing chemotherapy was in the 21-24 weeks 
gestational age group. The mean gestational age of patients with persistent CHM was 
slightly elevated compared to the mean gestational age of patients with uncomplicated 
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Table 4  Maternal age, incidence of CHM and the risk of requiring 
 chemotherapy (n=414)
Table 5  Gestational age and the need for chemotherapeutic treatment 
(n=414)
Age (yr)         <15 15-19 20-24 25-29 30-34 35-39 40-44 >44  Unknown
No. of CHM     0  39 73 118 82 51 27 18 6
No. of live births* 101 19315 84102 187059 184798 75634 12018 435 -
No. of CHM/     0 0.2 0.09 0.06 0.04 0.07 0.2 4.1 -
live births x 100%   
No. treated with     0 5 5 16 14 12 3 0 0
chemotherapy
% CHM treated    0 12.8 6.8 13.6 17.1 23.5 11.1 0 0
* Number of live births in the state of Victoria 1992-2000
Gestational age
(weeks) 0-4 5-8 9-12 13-16 17-20 21-24 25-28 >28 Unknown
No. of patients 1 142 155 51 19 3 0 0 43
No. of patients 0 16 16 10 3 1 0 0 9 
treated
% Treated 0 11 10 20 16 33 - - 21
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complete hydatidiform moles (11 compared to 10.12 weeks, P=0.15) although this 
difference did not reach statistical significance.
Repeat molar pregnancies
Two women with complete hydatidiform mole previously had another hydatidiform 
mole (prior to 1992, molar type unknown). Two patients had another complete molar 
pregnancy during the period of study. One patient had a subsequent CHM after the 
period of study. The incidence of repeat hydatidiform mole (only women with the first 
CHM between the years 1992-2000) in a pregnancy following a CHM in this study is 
0.7% (3 in the total of 431 patients). None of these three patients required chemothera-
peutic treatment. 
Complete hydatidiform moles with coexisting twin pregnancies
Complete hydatidiform mole was diagnosed together with a coexisting normal fetus in 
10 patients, giving an incidence of coexisting normal fetus pregnancies of 2.3% compared 
to the total of CHM patients and an incidence of 0.02% per 1000 live births. Only one out 
of the ten patients required chemotherapy for persistent trophoblastic disease. One 
patient had a twin pregnancy with a complete mole and a coexisting partial hydatidiform 
mole, chemotherapy was not required. The mean gestational age was significantly higher 
among the 11 twin pregnancies than among the total of uncomplicated and complicated 
cases analysed before (20.5 compared to 10.2, P=0.005). The maternal age was 
increased in women having a twin pregnancy compared with women with complicated 
and uncomplicated CHM without a twin, although this difference did not reach statistical 
significance (29.7 compared to 29.3, P=0.8).
ABO and rhesus blood groups and race
Differences in the frequency of ABO blood groups, rhesus blood groups and race 
among patients with CHM could not be calculated, because the number of patient files 
that contained this specific information was too small.
Discussion
Between the years 1992 and 2000, 433 cases of complete hydatidiform mole (CHM) 
were registered, giving an incidence of 1:1316 live births. The exact incidence is 
unknown, as the total number of pregnancies (inclusive live births, home abortions, 
induced abortions, still births and ectopic pregnancies) and the percentage of patients 
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referred to the registry are unknown. The total incidence of hydatidiform mole was 
1:730 live births, a rise compared to the population-based incidence of 1:1357 live 
births reported by Olesnicky et al. in 1985 [19]. The discrepancy in the incidence of 
hydatidiform moles might be due to an increased awareness of partial moles, as more 
spontaneous abortions are recognized as being partial moles. In Olesnicky’s report, 
only 13 partial moles were diagnosed compared to 442 complete moles, which may 
indicate an underestimation of the incidence of partial moles, while in the current study, 
the ratio of partial versus complete moles was 0.8:1. The rise of the incidence of 
hydatidiform moles can also be the result of a true increase in the incidence, perhaps 
because of increasing maternal age. This study revealed that the long period of 
follow-up has poor compliance. Only 16% of patients completed the entire period of 
hCG monitoring. High levels of non-compliance were also found in other studies [1,3]. 
While in this review, patient records were reevaluated retrospectively, it was not possible 
to determine whether the factors contributed to this significant non-compliance were 
only patient-related, or physician-related as well, for example if hCG tests were 
performed by a referring practitioner who did not send the results to the RWH, then no 
hCG assay results could be found in the patient record. In this study, 13.3% of patients 
with CHM required chemotherapy. The proportion of patients that develop PTD after a 
complete mole varies from 19–23% based on the criteria used to diagnose PTD (mostly 
based on hCG levels). Importantly, none of the patients who attained normal hCG 
values (urinary hCG < 2.5 and serum hCG < 2.0) had any evidence of persistent 
trophoblastic disease. This corresponds with the results of other studies [7-9]. The risk 
of persistent trophoblastic disease when hCG levels failed to normalise within 2 months 
after evacuation of a CHM was found to be 15% in this study. This is at variance with 
figures in previous reports. Lurain et al. and Curry et al. noted that 36–40% of patients 
that did not reach normal hCG levels by 2 months post-evacuation, required 
chemotherapy, which probably reflects a more active management approach to the 
patient with slowly falling levels [7,8]. These data show the expected increase of CHM 
in older age groups and an increase of chemotherapy in patients in older age groups, 
although the difference did not reach statistical significance. An increased risk of CHM 
in younger age groups was noted in this report and has also been observed in other 
studies [22]. Gestational age was higher among women with CHM who needed 
chemotherapy than among women with uncomplicated CHM; this difference was not 
statistically significant, comparable with other reports [19,20]. In this study, the risk for 
a second molar pregnancy after a CHM was 0.7%. This is comparable to previous 
studies [6,21,23]. Because the number of pregnancies following a complete mole 
could not be determined, and the patients included in this study were not monitored 
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until the end of their fertile life, exact risks of another molar pregnancy are uncertain. In 
contrast to previous reports, none of the three patients who had two molar pregnancies 
within the period of study required chemotherapy, although the number of cases is low 
[24]. There was one other study that reported no increased risk of chemotherapy after 
repeat CHM [22]. Ten patients had a complete hydatidiform mole with a coexisting 
normal twin pregnancy, giving an incidence of 2.3%. Gestational age was significantly 
higher in patients with a coexisting twin pregnancy than in patients with a ‘normal’ 
CHM. This is comparable with the gestational age of CHM with a coexisting twin 
pregnancies noted by Bruchim et al. Unlike previous studies, only one of the 10 patients 
needed chemotherapeutic treatment [25]. 
Conclusion
The risk of persistent trophoblastic disease after spontaneous normalisation of hCG in 
patients with a complete hydatidiform mole seems to be very low and may even 
approach zero. The results of this study support these findings, as none of the patients 
who had at least one normal hCG level, developed PTD. These findings are particularly 
significant for women whose hCG levels decline to normal levels within 2 months after 
evacuation of CHM, since no cases of recurrent persistent trophoblastic disease after 
spontaneous normalization have been reported in previous studies. For those women, 
a single normal hCG level is sufficient to assure sustained remission of trophoblastic 
disease. It is possible that there is a low risk of PTD after normalisation of hCG levels 
among women who not have normal hCG levels at 2 months after evacuation. Although 
Bagshawe might have overestimated the number of cases that attained normal levels 
more than 2 months post-evacuation and relapsed after, because relatively high levels 
of urinary and serum hCG were considered as normal (< 25 IU/L and < 5 IU/L, 
respectively), the risk of one in 96 women who developed PTD after normalising more 
than 2 months after evacuation is too high to be ignored [5]. Patients who failed to 
achieve normal hCG levels by 2 months after evacuation, should therefore be monitored 
with monthly hCG measurements for 1 year after normalisation to assure sustained 
remission.
chapter 3
61
3
References
 1. Massad LS, Abu-Rustum NR, Lee SS, Renta V. Poor compliance with postmolar surveillance and 
treatment protocols by indigent women. Obstet Gynecol 2000;96:940–944
 2. Wenzel L, Berkowitz RS, Newlands MD et al. Quality of life after gestational trophoblastic disease. J 
Reprod Med 2002;47:387–394
 3.  Feltmate CM, Batorfi J, Fulop V, Goldstein DP, Doszpod J, Berkowitz RS. Human chorionic 
gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. Obstet Gynecol 
2003;101:732–736
 4.  Wenzel LB, Berkowitz RS, Robinson S, Goldstein DP, Bernstein MR. Psychological, social and sexual 
effects of gestational trophoblastic disease on patients and their partners. J Reprod Med 
1994;39:163–167
 5.  Bagshawe KD, Wilson H, Dublon P, Smith A, Baldwin M, Kardana A. Follow up after hydatidiform 
mole: studies using radioimmunoassay for urinary human chorionic gonadotropin (HCG). J Obstet 
Gynecol Br Commonw 1973;80:461–468
 6.  Bagshawe KD, Dent J, Webb J. Hydatidiform mole in England and Wales 1973–83. Lancet 
1986;2:673–677
 7.  Curry SL, Hammond CB, Tyrey L, Creasman WT, Parker RT. Hydatidiform mole: diagnosis, 
management and longterm follow up of 347 patients. Obstet Gynecol 1975;45:1–8
 8.  Lurain JR, Brewer JI, Torok EE, Halpern B. Natural history of hydatidiform mole after primary 
evacuation. Am J Obstet Gynecol 1982;145:591–594
 9.  Batorfi J, Vegh G, Szepesi J, Szigetvari I, Doszpod J, Fulop V. How long should patients be followed 
after molar pregnancy? Analysis of serum hCG follow-up data. Obstet Gynecol 2004;112:95–97
 10.  Wolfberg AJ, Feltmate C, Goldstein DP, Berkowitz RS, Lieberman E. Low risk of relapse after 
achieving undetectable hCG levels in women with complete molar pregnancy. Obstet Gynecol 
2004;104:551–554
 11.  Wielsma S, Kerkmeijer L, Bekkers R, Pyman J, Tan J, Quinn M. Persistent trophoblast disease 
following partial molar pregnancy. Aust N Z J Obstet Gynaecol 2006;46:119–123
 12.  Sebire NJ, Rees H. Diagnosis of gestational trophoblastic disease in early pregnancy. Curr Diagn 
Pathol 2002;8:430–440
 13.  Fukunaga M. Immunohistochemical characterization of p57KIP2 expression in early hydatidiform 
moles. Human Pathol 2002;33:1188–1192
 14.  Cole Shahabi S, Butler SA, Mitchell H, Newlands ES, Behrman HR, Verrill HL. Utility of commonly 
used commercial human chorionic gonadotropin immunoassays in the diagnosis and management 
of trophoblastic diseases. Clin Chem 2001;47:308–315
 15.  National Health and Medical Research Council. When does quality assurance in health care 
require independent ethical review? 2003. http://www.nhmrc.gov.au/publications/_files/e46.pdf.
 16.  Riley M, Halliday J. Births in Victoria 1992–1996. Melbourne: Public Health Division, Department of 
Human Services Victoria
 17.  Riley M, Halliday J. Births in Victoria 1996–1998. Melbourne: Public Health Division, Department of 
Human Services Victoria
 18.  Riley M, Halliday J. Births in Victoria 1999–2000. Melbourne: Public Health Division, Department of 
Human Services Victoria
guidelines following hydatidiform mole: a reappraisal
62
 19.  Olesnicky G, Long AR, Quinn MA, Pepperell RJ, Fortune DW, Kneale BLG. Hydatidiform mole in 
Victoria: aetiology and natural history. Aust N Z J Obstet Gynaecol 1985;25:1–7
 20.  Kohorn EI. Hydatidiform mole and gestational trophoblastic disease in southern Connecticut. 
Obstet Gynecol 1982;59:78–84
 21.  Franke HR, Risse EKJ, Kenemans P, Vooijs GP, Stolk JG. Epidemiologic features of hydatidiform 
mole in the Netherlands. Obstet Gynecol 1983;62:613–616
 22.  Bandy LC, Clarke-Pearson DL, Hammond CB. Malignant potential of gestational trophoblastic 
disease at the extreme ages of reproductive life. Obstet Gynecol 1984;64:395–399
 23.  Lorigan PC, Sharma S, Bright N, Coleman RE, Hancock BW. Characteristics of women with 
recurrent molar pregnancies. Gynecol Oncol 2000;78:288–292
 24.  Rice LW, Lage JM, Berkowitz RS, Goldstein DP, Bernstein MR. Repetitive complete and partial 
hydatidiform mole. Obstet Gynecol 1989;74:217–219
 25.  Bruchim I, Kidron D, Amiel A, Altaras M, Fejgin MD. Complete hydatidiform mole and a coexistent 
viable fetus: report of two cases and a review of the literature. Gynecol Oncol 2000;77:197–202
chapter 3
63
3
guidelines following hydatidiform mole: a reappraisal

1CHAPTER
4CHAPTER
5CHAPTER
6CHAPTER
2CHAPTER
3CHAPTER
7CHAPTER
8CHAPTER
Recurrent gestational trophoblastic disease 
after hCG normalisation following hydatidiform 
mole in the Netherlands
Linda GW Kerkmeijer, Sabien Wielsma, Leon FAG Massuger, 
Fred CGJ Sweep, Chris MG Thomas
Gynecologic Oncology 2007; 106: 142-146
66
Abstract
Objectives: To determine the risk for recurrent trophoblastic disease after spontaneous 
normalisation of human chorionic gonadotropin (hCG) levels in patients with 
hydatidiform mole and to determine the risk for tumour relapse after apparent remission 
following chemotherapy in patients with low- and high-risk persistent trophoblastic 
disease. 
Methods: From 1994 until 2004, 355 patients with hydatidiform mole were registered at 
the Dutch Central Registry of Hydatidiform Mole and were monitored by sequential 
hCG assays in serum at the department of Chemical Endocrinology of the Radboud 
University Nijmegen Medical Centre. HCG regression curves were analysed together 
with clinical information collected from the Hydatidiform Mole Database.  
Results: Among the 355 registered hydatidiform mole patients, 265 patients attained 
spontaneous normalisation following evacuation. One patient subsequently required 
chemotherapeutic treatment for recurrent trophoblastic disease (95% confidence 
interval 0.0% to 2.1%). HCG levels did not decline to normal (<2.0 ng/mL) spontaneously 
in 90 patients; those patients were subsequently treated. Relapse rates were 8.1% 
(6/74) and 6.3% (1/16) for the low- and high-risk category respectively.  
Conclusion: Our analysis indicates that relapse risk in hydatidiform mole patients with 
spontaneous normalisation is extremely low (one in 265 patients) after two normal hCG 
levels (< 2.0 ng/mL) are achieved. Our results support the suggestion that two 
subsequent normal hCG levels may be sufficient to ensure sustained remission after 
hydatidiform mole evacuation. In contrary, in order to assure sustained remission, the 
relapse rates after chemotherapy in the current study emphasize the need for 
surveillance of trophoblastic tumour patients even after complete remission has 
apparently been achieved.
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Introduction
Hydatidiform mole (HM) is a vesicular or polycystic mass resulting from proliferation of 
the trophoblast that can be detected by ultrasound [1,2]. When molar pregnancy is 
suspected, suction curettage is the standard mode of evacuation of the molar tissue 
[3]. Two entities of hydatidiform mole, complete and partial mole, can be distinguished 
in terms of epidemiology, gross morphology, histopathology and karyotype, but many 
of their clinical features and their basic management are similar. Histopathologic and 
flowcytometric analysis can be helpful to make a distinction between complete HM, 
partial HM and hydropic abortion [4-6]. The incidence of HM in Europe and North 
America is approximately 0.5 to 1 in 1000 pregnancies, but varies with incidence rates 
from 2 up to 12  per 1000 pregnancies in South-East Asia, Indonesia, India and Turkey 
[7].  Patients with hydatidiform mole are at increased risk of persistent trophoblastic 
disease (PTD). The risk of PTD ranges from 0.5% to 20 %, including both complete and 
partial moles [8-10]. Because of its high sensitivity to chemotherapy, PTD is one of the 
best curable tumours, even in case of relapse after primary remission [11,12]. 
Human chorionic gonadotropin (hCG) is a glycoprotein hormone composed of an 
α- and β-subunit and is produced by the trophoblast. It can be measured in both 
serum and urine. Therefore, hCG is proved an ideal marker to monitor trophoblastic 
activity, treatment response and to detect tumour relapse [13]. To detect PTD, accurate 
hCG follow-up is essential for all women diagnosed with hydatidiform mole pregnancy 
after evacuation of the molar tissue. Bagshawe et al. found in 1986 that recurrence of 
PTD after spontaneous normalisation of hCG levels occurred, therefore a follow-up 
protocol is being used worldwide after normalisation [14]. Follow-up guidelines include 
at least six months of monitoring after normalisation of hCG levels. However, long term 
monitoring delays childbearing, causes patient anxiety and stress, is resource intensive 
and has a poor compliance [10,15,16]. Recent studies using sensitive hCG assays 
reported no evidence of PTD after spontaneous normalisation, suggesting that the 
interval of monitoring may be shortened without compromising patient health and 
safety [10,17-21].
The current follow-up protocol after chemotherapeutic treatment of PTD is based on 
clinical experience. Although the risk of tumour relapse is low, several studies found 
that after chemotherapy PTD can recur in approximately 2.2-5.3% of cases [11,22,23]. 
Late recurrences are rarely observed, but have been reported to occur up to 72 months 
after chemotherapy [12]. Hence, sustained hCG follow-up is crucial for all patients 
treated for PTD. The present study was undertaken to review the current follow-up 
protocol of hydatidiform moles in The Netherlands, particularly related to the risk of 
recurrent gtd after hcg normalization in hm
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recurrent PTD after spontaneous hCG normalisation and related to the incidence of 
tumour relapse after apparent remission following chemotherapy in patients with low- 
and high-risk PTD. 
Materials and methods
The Dutch Central Registry of Hydatidiform Mole was established at the Radboud 
University Nijmegen Medical Centre (RUN MC) in May 1977. The Dutch Registry mainly 
serves as an epidemiological database and provides advice to the gynaecologists in 
attendance if required. For many patients hCG measurements are performed centrally 
in the department of Chemical Endocrinology of our hospital. Patients with GTD can be 
monitored with hCG assays and treated in hospitals elsewhere. After informed consent, 
patients were registered. From 1994 until 2004, 355 patients with hydatidiform mole 
were monitored by sequential hCG assays in serum at the RUN MC after evacuation of 
the molar tissue. HCG regression curves were constructed for these patients and 
analysed together with clinical information collected from the Hydatidiform Mole 
Database. According to the treatment protocols of the Dutch Society of Obstetrics and 
Gynaecology, hCG follow-up recommendations include weekly hCG measurements 
until normal hCG serum levels (<2.0 ng/mL) were achieved for 4 weeks. Following this, 
monthly hCG determinations are performed for 6 months. This is in accordance with 
the guidelines developed by the International Federation of Gynecology and Obstetrics 
(FIGO) [24]. Patients with HM were considered to have had spontaneous sustained 
remission of molar disease after evacuation, when hCG measurement indicated 
spontaneous regression of hCG values to less than 2.0 ng/mL and remained so for at 
least 6 months without clinical evidence of residual disease. In case of a rise or plateau 
of hCG titres in 3 subsequent weeks and at least one value exceeding the 95th percentile 
of the normal hCG regression corridor constructed in 1993 by Yedema et al. [25], 
persistent disease was diagnosed and treatment was instituted. PTD following HM was 
primarily treated with methotrexate (MTX) and folinic acid rescue (low-risk PTD).  MTX 
treatment was given until normal hCG levels were obtained, and for two full courses 
afterwards to assure sustained remission. High-risk PTD (MTX resistance, metastatic 
disease other than vaginal and lung metastases, metastatic disease in more than one 
organ outside the uterus and in case the interval between evacuation and chemotherapy 
exceeded 12 months) was treated with multiagent chemotherapy, mainly EMA/CO 
(etoposide, MTX, actinomycin D, cyclophosphamide, oncovin). The Dutch guidelines 
recommend follow-up of patients with low-risk PTD for one year after normalisation 
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with monthly hCG assays, and patients with high-risk PTD with monthly measurements 
for two years. Because early detection of disease recurrence is prevented by the 
increasing hCG levels of pregnancy, all patients were advised to avoid pregnancy for 
one year after normal values were obtained. Recurrent PTD was defined as the need 
for chemotherapeutic treatment or hysterectomy after normalisation of hCG levels for 
at least two subsequent measurements. The criterion of a second normal hCG level 
was added to decrease the impact of a false negative test result. The Central Registry 
laboratory provides a national hCG assay service. All serum-hCG measurements were 
performed by means of a sensitive and specific radioimmunoassay (RIA), developed 
in our Nijmegen laboratory, using a polyclonal antiserum that measures both native 
and free β-subunits (hCG + hCG-β) [26]. All test results were expressed in ng/mL. 
The analytical sensitivity of the assay is 1.0 ng/mL. 
The upper limit of normal was established at 2.0 ng/mL, representing the cut-off serum 
concentration at 95% specificity as found in post-menopausal females and hypergona-
dotropic males. 
Results
Of the 355 patients who were monitored with serial hCG measurements after HM 
evacuation, 265 patients entered spontaneous remission (mean age 29.7 years, range 
15 to 50 years). Patients were divided into various categories according to the length 
of the follow-up period after normalisation (Fig. 1).
Spontaneous normalisation group
Among the 265 patients, 145 patients had a follow-up period of less than 6 months, 
while 100 patients had a follow-up period ranging from 6 to 12 months and 20 patients 
were followed for more than 12 months after normal hCG levels were achieved. One 
patient required chemotherapeutic treatment for recurrent trophoblastic disease after 
attaining 2 normal hCG levels (95% confidence interval 0.0% to 2.1%). All patients 
except-one attained normalisation within 26 weeks, with a median interval of 7 weeks.
Case report of the only patient with recurrent GTD
A 31-year-old-women (gravida 4, para 2) presented with abnormal vaginal bleeding at 
9 weeks of gestation. Ultrasound was suggestive of hydatidiform mole. Suction 
curettage was performed two days later. The diagnosis of complete HM was made on 
histological diagnosis and confirmed by a  RUN MC pathologist. Ploidy studies also 
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supported this diagnosis. X-thorax showed no abnormalities. Initial serum concentrations 
of hCG decreased to normal after evacuation (in-house hCG + hCGβ RIA: 2.2 ng/mL 
at 8 weeks, 1.6 ng/mL at 12 weeks, 1.2 ng/mL at 13 weeks). However, serum hCG 
concentrations started to increase 16 weeks after evacuation up to 4.9 ng/mL. Therefore 
the first course of MTX was administered 23 weeks after evacuation. After the second 
course of methotrexate, hCG-levels became undetectable. Two more courses were 
administered to reassure sustained remission. The patient completed the recommended 
one-year of monthly follow-up and became pregnant 16 months after hCG had 
decreased to undetectable concentrations. She delivered a healthy son and after 
delivery there was no clinical evidence of residual disease.
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Number of HM patients with hCG
regression curves*
n=355 
Spontaneous normalisation
n=265
 No spontaneous normalisation
n=90
 
No recurrence
n=264
Follow-up period:
Recurrence
n=1
Follow-up period:
Low-risk PTD
n=74
Follow-up period:
High-risk PTD
n=16 
Follow-up period:
<6 months n=144
6-12 months n=100
>12 months n=20
>12 months n=1 <6 months n=23
6-12 months n=35
12-24 months n=14
>24 months n=2
<6 months n=7
6-12 months n=1
12-24 months n=4
>24 months n=4
Recurrence
n=1
No recurrence
n=15
Recurrence
n=6
No recurrence
n=68
Figure 1  HCG follow-up in hydatidiform mole patients and the risk of 
 recurrent trophoblastic disease
HM; hydatidiform mole, hCG; human chorionic gonadotropin, PTD; persistent trophoblastic disease
* More than 2 normal serum hCG determinations (performed in RUNMC, Department of Chemical 
Endocrinology; Evacuation date and treatment (outcome) known
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PTD group
An initial increase or plateau of hCG serum concentrations was attained in 90 patients 
(mean age 30.7 years, range 20 to 46 years).  Eighty-nine patients were commenced on 
MTX, one patient was primarily treated with hysterectomy. Seventy-four (83%) of the 89 
patients achieved normal hCG titres on methotrexate alone and were therefore classified 
as low-risk patients, while 16 (17%) were classified as high-risk patients. In the case of 
15 patients who developed MTX resistance or severe toxic reactions, drug regimens 
were changed to high-risk multiagent chemotherapeutic treatment. For one high-risk 
patient diagnosed with choriocarcinoma the primary treatment of choice was 
hysterectomy. Among the 74 patients in the low-risk category 23 were followed for less 
than 6 months after normalisation of their serum hCG concentrations after treatment, 35 
for 6 to 12 months, 14 patients for 12 to 24 months and 2 patients had a follow-up period 
longer than 24 months. Of the 16 patients in the high-risk category, 7 patients were 
monitored for serum hCG less than 6 months after treatment, 1 patient was followed up 
for 6 to 12 months, 4 patients between 12 and 24 months and 4 patients for more than 
24 months. Primary remission was achieved in all 74 low-risk patients treated with MTX. 
Six (8.1%) patients developed recurrent trophoblastic tumour. The median duration of 
remission after low-risk treatment prior to the first day of treatment in case of relapse was 
13 weeks (range, 6 to 35 weeks). All 16 high-risk patients (including one patient initially 
treated with hysterectomy) gained primary remission. One (6.3%) out of the 16 high-risk 
patients relapsed at 14 weeks after treatment. All 7 patients with recurrent trophoblastic 
disease were treated successfully and remained free of residual disease up till now.
Discussion
This study was based on patients with spontaneous normalisation of hCG levels after 
HM evacuation and after normalisation following PTD, monitored centrally by sequential 
hCG assays in serum at the Department of Chemical Endocrinology in our hospital. 
HCG regression curves were constructed for these patients. Persistent disease was 
diagnosed in case of a rise or plateau of hCG titres in 3 subsequent weeks and at least 
one value exceeding the 95th percentile of the normal hCG regression curve presented 
in 1993 by Yedema et al [25]. Patients with GTD can be monitored with centralised hCG 
assays and treated in hospitals elsewhere. Since registration is voluntary, the Central 
Registration does not cover all hydatidiform moles in our country. Due to the complexity 
of the management of persistent disease, patients with PTD are more likely to be 
registered than uncomplicated cases of HM.
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Spontaneous normalisation group
In 1986 Bagshawe et al. reported on 27 HM patients who relapsed after achieving at 
least one normal hCG value of less than 5 mIU/mL in serum and/or less than 25 mIU/mL 
in urine. They defined two groups of patients with spontaneous normalisation. The first 
group of 2169 patients with a spontaneous decline and normal hCG levels within 56 days 
of evacuation all remained free of disease. Of the remaining 2585 patients that became 
normal more than 56 days after evacuation, 27 patients (1.0%) subsequently developed 
recurrent trophoblastic disease [14]. Persistent disease was defined as a rise of hCG 
levels for 2 consecutive weeks or a plateau for 3 weeks without the use of a normal hCG 
regression curve. Recent studies suggest that current follow-up guidelines might be 
revised. In the study of Feltmate et al., none of the 320 patients with spontaneous hCG 
regression to undetectable concentrations developed gestational trophoblastic tumour 
[10]. In 2004 Batorfi et al. reported that among 120 HM patients with at least one 
undetectable hCG level, none had any evidence of relapse [18]. Wolfberg et al. reported 
on the risk of relapse after that undetectable levels were achieved following complete 
hydatidiform mole evacuation [9]. Before 1993, when the hCG assay used had a 
sensitivity of less that 10 mIU/mL, 2 of the 876 patients whose hCG values spontaneously 
declined to undetectable levels, subsequently relapsed. None of the patients analysed 
after 1993 relapsed, when assays with a sensitivity of less than 5 mIU/mL were used [9]. 
In the study of Lavie et al. none of the 74 patients had evidence of recurrence after 
attaining normal hCG concentrations of less than 5 mIU/mL after evacuation of partial 
HM [17]. Recent studies in Victoria, Australia, reported that none of the 344 partial and 
none of the 433 complete HM had recurrent trophoblastic disease following spontaneous 
normalisation [19,20]. None of the 238 partial mole patients with a complete hCG 
follow-up (greater than 6 months) observed by Wolfberg et al., developed PTD after 
achieving undetectable hCG levels [21]. In the present study we report that among the 
265 patients with spontaneous normalisation, one patient developed gestational 
trophoblastic tumour after initially achieving two normal hCG values according to the 
RUN MC assay. The incidence of recurrence after initial normalisation mainly depends 
on variations in the exact criteria used to define normalisation and variations in the 
sensitivity of the hCG assays applied. To prevent too intensive follow-up in uncomplicated 
cases of HM, it is important to define normalisation accurately. To assure normalisation, 
a second normal hCG level was added. Our analysis indicates that relapse after at least 
two normal hCG levels 2.0 ng/mL) occurred only once in 265 patients. 
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PTD group 
Nowadays, chemotherapeutic treatment has shown to be highly effective in the 
management of trophoblastic tumour. Primary remission rates are high, although there 
is a considerable risk of tumour relapse [11,22,23]. Relapse rates largely depend on 
the treatment given, especially treatment type and the number of courses of 
chemotherapy administered after normalisation to eradicate the remaining 
(undetectable) trophoblastic activity. In the present study 7 out of the 90 patients 
treated for PTD developed recurrent trophoblastic tumour. Seventy-four (82%) of the 
patients achieved primary remission (at least two consecutive hCG levels less than 2.0 
ng/mL) with single-agent MTX alone, 6 (8.1%) subsequently relapsed. This is not in 
accordance with previous reports (relapse rates 2.0-5.0%), in our study relapse rates 
after MTX are slightly higher [11,22,23]. Sixteen (18%) patients were classified as 
high-risk patients, 15 of these patients were instituted on multiagent chemotherapy, 
which was in all cases preceded by MTX and one patient was primarily treated with 
hysterectomy. Of these 16 high-risk patients, one (6.3%) patient required treatment for 
a recurrent episode of trophoblastic tumour. The number of patients is too low to be 
compared to other studies. Our results indicate that most recurrences after chemo-
therapeutic treatment occur within the recommended follow-up episode. In our study 
all 6 patients relapsed within 12 months after completing chemotherapy in the low-risk 
category and the single case of recurrence among the high-risk patients relapsed 
within 24 months. All 7 patients achieved secondary remission and remained free of 
residual disease. In conclusion, our results support the suggestion that the burden of 
long term follow-up after spontaneous normalisation may be diminished by shortening 
the interval of monitoring without compromising patient health and safety. In contrary, 
the relapse rates after chemotherapy in the current study emphasizes the need for 
surveillance of trophoblastic tumour patients even after complete remission has 
apparently been achieved, to assure sustained remission. Rising hCG of pregnancy 
can prevent early detection and diagnosis of disease recurrence, therefore it remains 
advisable to avoid pregnancies for one year after chemotherapeutic treatment of 
trophoblastic tumour.
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Abstract
Objective: To investigate whether the glycoform distribution patterns of human chorionic 
gonadotropin (hCG) obtained by chromatofocusing in pre-evacuation serum can 
predict development of persistent trophoblastic disease in complete hydatidiform mole 
pregnancy.
Methods: Blood samples were collected from women with complete hydatidiform mole 
with uneventful spontaneous regression after molar evacuation ( n = 32), from women 
with complete hydatidiform mole who developed persistent trophoblastic disease  after 
evacuation of their mole (n = 28) and, as a control group, from women during the first 
trimester of normal pregnancy (n = 22). The obtained serum specimens were subjected 
to chromatofocusing, and hCG was determined in the fractions collected in the pH 
range 7.0-3.0. 
Results: Receiver Operating Characteristics (ROC) analysis revealed that 36 % of 
complete hydatidiform mole patients with post-molar persistent trophoblastic disease 
development could have been predicted at 97 % specificity (pH interval 6.3-5.1, hCG 
cut-off 9.9%). Comparison of hCG percentages among complete hydatidiform mole 
with and without persistent trophoblastic disease for pH interval 6.3-5.1 showed 
p <0.0003. 
Conclusion: Assessment of the hCG glycoform profiles in pre-evacuation serum 
samples from patients with complete hydatidiform mole can predict future development 
of persistent trophoblastic disease at sensitivity rates of 36 % with 97 % specificity. 
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Introduction
The glycoprotein hormone human chorionic gonadotropin (hCG) originating from 
trophoblastic tissue, is a key marker in pregnancy and gestational trophoblastic disease 
[1]. After molar evacuation, trophoblastic activity does not disappear spontaneously in 
case of persistent trophoblastic disease . The reported frequency of persistent 
trophoblastic disease is 20% in complete hydatidiform mole [2] and 0.5 to 9.9% in partial 
hydatidiform mole [3-6]. In order to prevent complications of local invasiveness and 
metastatic spread persistent trophoblastic disease needs to be treated. According to 
FIGO 2000 criteria, the diagnosis of persistent trophoblastic disease is based on a 
plateau or rise of consecutive hCG levels following evacuation of the molar tissue [7]. 
Dependent on the persistent trophoblastic disease risk category, single-agent 
chemotherapy (low-risk) or combination chemotherapy (high-risk) is generally instituted. 
In an experimental setting, one course of prophylactic chemotherapy was administered 
at time of, or shortly after evacuation to prevent persistent trophoblastic disease in 
complete hydatidiform mole. Unfortunately, this resulted in a high proportion of needless 
chemotherapeutic treatment. In two randomized prospective studies prophylactic 
chemotherapy was used in a subset of patients at increased risk of persistent trophoblastic 
disease  (for instance pre-evacuation hCG > 100,000 IU/L). This resulted in a significant 
decrease in the development of persistent trophoblastic disease from approximately 
50% to 14% [8,9]. Nevertheless, in these trials, the use of prophylactic chemotherapy 
was redundant for 50% of complete hydatidiform mole patients, since these patients 
would have shown spontaneous remission after molar evacuation. Furthermore, 
chemotherapy is associated with several side effects, therefore the use of prophylactic 
chemotherapy is controversial. It would be helpful to identify patients at risk for developing 
persistent trophoblastic disease  at high specificity in an early stage.
The glycoprotein hormone hCG (Mr 37,500) is composed of two non-covalently bound 
subunits, α and β, all of which are produced in high concentrations during pregnancy. 
The production of (subunits of) hCG is reported to be different in pathological states 
such as hydatidiform mole [10-14]. The concentration of hCGβ and the ratio of hCGβ 
to hCG + hCGβ is reported to be increased in molar as compared with normal 
pregnancy [15]. Some studies, using a limited number of patients, reported that an 
increased ratio of hCGβ to hCG + hCGβ identifies patients with molar pregnancy who 
are at risk for developing persistent trophoblastic disease [16-18], although other 
investigators could not confirm such an association [12].
Glycosylation is an important posttranslational modification process in proteins, and 
aberrant glycosylation occurs in malignancies [19,20]. The presence of terminal sialic 
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acid (and/or sulphate) attached to the eight carbohydrate side chains of hCG causes 
a longer passage time in blood which appears crucial for biological action [21]. Due to 
the anionic character of these carbohydrates, the net charge distribution patterns of 
glycoprotein hormones can be determined with high-resolution chromatofocusing 
procedures. In previous studies, including one from our group, distribution patterns of 
the glycoprotein hormones follicle stimulating hormone (FSH) and luteinising hormone 
(LH) in cyclic and postmenopausal women have been explored [22,23]. The present 
retrospective study aimed to investigate whether the hCG glycoform distribution 
patterns in serum taken prior to complete hydatidiform mole evacuation can predict 
post-molar development of persistent trophoblastic disease.
Materials and Methods 
Patients
In The Netherlands, patients with hydatidiform mole are registered, after informed 
consent, at the Dutch Central Registry for Hydatidiform Moles residing at the Radboud 
University Nijmegen Medical Centre. From 1977 to 2008, we have included 3545 patients 
in this database. In 692 registered patients with hydatidiform mole, hCG in blood, 
obtained after molar evacuation, was analyzed in our department. After collection, blood 
samples were centrifu ged and serum was sent to our institute for routine hCG 
measurement and subsequently stored at -35 °C in our serum bank. The serum bank 
contained a limited number of 32 pre-evacuation samples with sufficient amounts of 
serum from patients with complete hydatidiform mole without persistent trophoblastic 
disease and 28 pre-evacuation samples from patients with complete hydatidiform mole 
who subsequently developed persistent trophoblastic disease  after molar evacuation. 
The normal pregnancy group comprised 22 women with uneventful pregnancies, whose 
blood was collected between 10 and 16 weeks of gestation. Histo-pathologic criteria for 
the diagnosis of complete hydatidiform mole had been described recently [24]. In case 
of doubt, the histopathological diagnosis was centrally reviewed by a specialized 
pathologist, including, in recent years, flowcytometric analysis or immunohistochemistry 
(p57 Kip). In accordance with the criteria of the Dutch Society for Obstetrics and 
Gynecology, persistent trophoblastic disease was defined as three weekly static or rising 
hCG levels and at least one measurement above the 95th percentile line of the normal 
hCG regression curve as described by Yedema et al. [25,26].  The study has been carried 
out in the Netherlands in accordance with the applicable rules concerning the review of 
research ethics committees and informed consent. 
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Immunoassay for serum hCG
Serum specimens were assayed in retrospect with an intact hCG radioimmunoassay 
(RIA) based on a privately developed polyclonal antibody raised in rabbits against 
intact hCG. The minimum detectable concentration significantly different from zero 
with this assay was 1.0 ng/mL. The assay precision was tested in 64 consecutive assay 
runs with a low, medium and high serum hCG pool. The intra-assay and inter-assay 
coefficients of variation (CV) were, respectively, 10% and 14% for the low serum pool 
(mean: 3.4 ng/mL), 5.5% and 7.5% with the medium serum pool (mean: 26 ng/mL), 
and 7.9% and 10% with the high serum pool (mean: 46 ng/mL). All assays were 
performed blinded for disease outcome.
Chromatofocusing
All buffers used were prepared with high purity deionized water (resistivity > 10 
MΩ*cm, Elgastat Maxima – HPLC Ultrapure Water, Elga Ltd, High Wycombe, Bucks, 
England). The start buffer was bis(2-hydroxyethyl)imino-tris(hydroxymethyl)methane 
(bis-tris, 7.14 mM, pH 7.0-7.1, Sigma). The elution buffer for chromatofocusing on fast 
performance liquid chromatography (FPLC) was Polybuffer 74 (GE Healthcare 
Biosciences AB, Uppsala, Sweden) used at a dilution of 1:35, pH 3.1-3.2. Both buffers 
were pH-adjusted with saturated iminodiacetic acid (Sigma) prior to filtering through a 
0.22-µm bottle filter (Millipore). The pH of the effluent FPLC fractions were neutralised 
with 50 µL of 0.8 M phosphate buffer containing 0.2 % NaN3 (PBS, pH 7.4). 
Serum specimens were desalted on a PD-10 column (GE Healthcare Biosciences). 
First, the column was rinsed with 30 mL bis-tris containing 0.1 % (w/v) BSA, and 2.5 mL 
of serum specimen pre-diluted with PBS to a final concentration of 600 ng of hCG per 
mL was pipetted onto the column, eluted with 3.5 mL bis-tris, collected and made up 
to a final volume of 10 mL with the bis-tris buffer. Of this sample, 8.5 mL was injected 
onto the equilibrated Mono-P column (GE Healthcare Biosciences).
An FPLC system (GE Healthcare Biosciences) equipped with a 4-mL Mono-P column 
HR 5/200 was used for chromatofocusing. The storage counter ion of the Mono-P 
column resin was exchanged by washing with 2 mL of a 2 M NaCl solution. Next, the 
column was equilibrated with 30 mL bis-tris at a flow rate of 0.5 mL/min, which was 
normally sufficient to reach an effluent pH equal to that of the start buffer. The superloop 
was subsequently loaded with 8.5 mL of the diluted sample, and the 2-mL loop with 2 
mL 2 M NaCl. The sample in the superloop was loaded onto the column. The pH 
gradient was generated by introduction of the elution buffer at a flow rate of 0.5 mL/
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min. To neutralise the pH of the column effluent, effluent fractions of 2 mL were collected 
into tubes containing 50 µL 0.8 M PBS with 4.5 % (w/v) BSA. Every fifth tube only 
contained 4.5% BSA as these tubes were used to determine the pH gradient of the 
effluent running off the Mono-P column. The pH was determined with a pH meter 
(Metrohm 744, Metrohm AG, Herisau, Switzerland) equipped with a combined glass 
electrode. After collection of 140 mL effluent, the pH was 3.2. In order to elute all 
proteins with pI <3.5 (salt peak) the column was washed with the NaCl solution 
contained in the 2-mL loop. Fractions of another 5 x 2 mL of FPLC elution buffer were 
collected. Finally, the column was regenerated with 2 mL 2 M NaOH and 50 mL bis-tris. 
The pH in each fifth 2-mL fraction was determined directly after collecting these effluent 
fractions. Immediately after this, these solutions were also neutralised with 50 µL 0.8 M 
PBS. Next, the hCG concentrations were determined in all individual effluent fractions 
up to the salt peak effluents.
Statistics 
The hCG concentrations in all collected effluent pH fractions were corrected for 
procedural losses by taking the quantity of hCG loaded onto the Mono-P column as 
100%, and the sum of all the pH fractions including the salt peak fractions as the total 
amount recovered. From these corrected data we calculated the relative amounts of 
hCG at fixed pH values of pH 7.0, 6.9, 6.8, until pH 3.0 by interpolation. In order to 
achieve the largest discriminatory capacity between the complete hydatidiform mole 
group with and without persistent trophoblastic disease we determined for which pH 
interval (i.e., sum of the relative amounts of hCG present in several consecutive fixed 
pH fractions) the difference between the sums of the hCG amounts in the two groups 
was largest. PH intervals consisted of three or more (up to 15) consecutive pH fractions 
(for instance, pH interval size 3 for pH 6.7 through pH 6.5, and pH interval size 15 for 
pH 6.7 through pH 5.3). For each pH interval size we tested the cumulative amounts of 
hCG in the range from pH 7.0 until 3.0 and determined the p-value between the 
complete hydatidiform mole  group with and without persistent trophoblastic disease 
by means of the Student’s t-test. Normality of distribution was tested by use of the 
Kolmogorov-Smirnov test and frequency distribution histograms. Differences in 
parametrical data were calculated by means of the two-tailed Student’s t-test. Non-
parametrical data were assessed by use of the two-tailed Mann-Whitney U test. 
Frequency distributions were compared by means of the Pearson’s chi-square test 
and in case of expected counts < 5 by Fisher’s exact test. Receiver operating 
characteristics (ROC) curves were constructed to determine hCG cut-off levels and 
sensitivity at given specificity to distinguish cases of complete hydatidiform mole with 
chapter 5
83
5
future development of persistent trophoblastic disease from those with spontaneous 
regression. All calculations were conducted with SPSS (version 16.0, SPSS, Chicago, 
IL, USA) for Microsoft Windows XP. We adhered to the REMARK-criteria wherever 
appropriate [27].
Results
Maternal age was higher in normal pregnancy when compared with complete 
hydatidiform mole  without (p = 0.01) and with persistent trophoblastic disease  (p = 
0.001) (mean: 35.0, 30.6 and 29.8 years, respectively). Gestational age was not 
significantly different in normal pregnancy compared with uneventful complete 
hydatidiform mole and complete hydatidiform mole  with persistent trophoblastic 
disease  (mean: 11.7, 11.6, and 11.7 weeks, respectively). No statistical significant 
differences were observed for maternal and gestational age between the patients with 
uneventful complete hydatidiform mole or those with subsequent persistent 
trophoblastic disease development. 
Chromatofocusing distribution patterns of hCG glycoforms
Figure 1 shows the chromatofocusing distribution patterns of hCG glycoforms of all 
pregnant women . Figure 1A depicts the hCG glycoform patterns of normal pregnancy 
(n = 22) while Figure 1B and 1C show the distribution patterns observed in pre- 
evacuation serum of complete hydatidiform mole  without persistent trophoblastic 
disease  (n = 32) or with future development of persistent trophoblastic disease  (n = 
28), respectively. All three hCG glycoform patterns show the majority of recovered hCG 
in the pH range between 5.3 and 3.5. In the pH range from 7.0 to 5.3, relatively higher 
percentages of hCG were found in the group of normal pregnant women (A) followed 
by lower percentages of hCG in the complete hydatidiform mole group with development 
of persistent trophoblastic disease (C), while minimum percent rates of hCG were 
observed in the complete hydatidiform mole group without persistent trophoblastic 
disease (B).
We compared the differences in the percent rates of hCG for the complete hydatidiform 
mole  groups with and without persistent trophoblastic disease  throughout the entire 
pH range for several pH interval sizes. Because the percent rates of hCG of individual 
pH fractions are rather low, we used the cumulative sum of hCG percentages from 
three up to 15 consecutive 0.1-pH fractions. 
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Figure 1  pH profile of chromatofocusing of intact hCG (mean % hCG per pH 
fraction + 1 standard deviation) in normal pregnancy (A), complete 
hydatidiform mole without (B) and complete hydatidiform mole with 
persistent trophoblastic disease (C)
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For each of these pH interval sizes, we calculated the p-values over the entire pH 
range, with the upper pH value of each pH interval indicated on the x-axis of Figure 2. 
Significant differences with p-values  <0.01 were observed with all pH interval sizes, 
and p-values were  <0.001 with all pH interval sizes except pH interval sizes 3, 4 and 
5. PH interval sizes 13, 14, and 15 showed p-values as low as <0.0003 at pH 6.3, 6.4 
and 6.5, respectively (Figure 2). ROC curve analysis of pH interval size 13 at upper pH 
level of 6.3 is depicted in Figure 3, resulting in a sensitivity of 36% at 97% specificity 
(cut-off level 9.9%). The diagnostic accuracy (i.e. area under the curve, AUC) was 0.80 
(95% confidence interval 0.69-0.91). Comparable results were obtained in the case of 
pH interval sizes 14 and 15 (data not shown).
Gestational age has shown to be significantly different in the persistent trophoblastic 
disease patients that could have been predicted by their pH profile of hCG (mean 10.4 
weeks, SD 1.6 weeks) in comparison with the patients that could not (mean 13.0 weeks, 
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SD 2.4 weeks, p=0.008). Pre-evacuation hCG level, maternal age, the number of 
methotrexate (MTX) or poly-chemotherapy courses, the presence of low- versus 
high-risk persistent trophoblastic disease and the presence of metastatic spread were 
not significantly different between the persistent trophoblastic disease  patients that 
could, or could not have been predicted by their pH profile of hCG.
Discussion
In the present study we have explored whether chromatofocusing of hCG in a 
pre-evacuation blood sample of women with complete hydatidiform mole is useful for 
the prediction of persistent trophoblastic disease. Over a broad range of tested pH 
values we observed highly significant differences between the cumulative hCG percent 
rates of patients who will develop persistent trophoblastic disease as compared to 
those who will not. As a result, as much as 36% of complete hydatidiform mole patients 
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Figure 3  Receiver operating characteristics curve comparing the sum of 
hCG percentages derived from pH interval size 13 (pH 6.3-5.1) 
among complete hydatidiform mole with and without persistent 
 trophoblastic disease 
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who will eventually develop persistent trophoblastic disease can be predicted by 
means of the distribution patterns of the hCG glycoforms at 97% specificity. This 
finding suggests that the malignant signature in hydatidiform moles that develop 
persistent trophoblastic disease, is already present prior to evacuation in at the least 
a portion of complete hydatidiform mole  patients. However, the precise mechanism 
underlying the development of persistent trophoblastic disease remains to be 
elucidated. Besides differences in gestational age, we have not observed significant 
differences in clinical characteristics among the persistent trophoblastic disease 
patients that could be detected by pH distribution of hCG in pre-evacuation serum and 
the patients that could not. Although the patient numbers were relatively low, these 
findings suggest that the predictability of patients who will develop persistent 
trophoblastic disease by their chromatofocusing pattern cannot be attributed to a 
particular clinical feature, e.g., high-risk persistent trophoblastic disease. 
Up till now, the diagnosis of persistent trophoblastic disease is based on serial rising 
or static hCG levels following molar evacuation. According to the widely accepted 
International Federation of Gynecology and Obstetrics (FIGO 2000) criteria, persistent 
trophoblastic disease is defined as 1) a plateau in weekly serum hCG concentrations 
for 3 consecutive weeks, 2) an increase of the serum hCG level for 2 weeks, or 3) 
persistence of detectable hCG levels for more than 6 months after evacuation [7]. In 
The Netherlands, the Dutch Society for Obstetrics and Gynecology defines persistent 
trophoblastic disease as a plateau or rise in three serial weekly hCG levels and at least 
one measurement above the 95th percentile line of the normal hCG regression curve as 
described by Yedema et al. [25,26]. This criterion is added since 15% of mole patients 
with a plateau or rise in hCG levels who did not exceed the 95th percentile line, eventually 
achieved spontaneous serum hCG normalization [25,26]. One of the reasons why 
prophylactic chemotherapy given prior to or shortly after evacuation is not widely 
implemented, is the high proportion of patients that receive unnecessary chemothera-
peutic treatment. Even in two studies where prophylactic chemotherapy was reserved 
for those at increased risk of persistent trophoblastic disease  (for instance with 
pre-evacuation hCG levels > 100,000), the proportion of needless treatment of 
uneventful complete hydatidiform mole did not reach acceptable levels, since 
redundant chemotherapeutic treatment with associated toxicity occurred in 
approximately 50% of those patients [9,10]. Prophylactic chemotherapy, although 
effective in diminishing persistent trophoblastic disease occurrence, remains therefore 
controversial. However, it might be appropriate when persistent trophoblastic disease 
in complete hydatidiform mole patients is predicted at very high specificity (minimizing 
redundant treatment) such as shown in the present study. 
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Currently, a prognostic tool to predict persistent trophoblastic disease is lacking and 
persistent disease can only be diagnosed at several weeks or months after molar 
evacuation. Generally accepted biochemical markers for prediction of persistent 
trophoblastic disease prior to the clinical detection of persistent trophoblastic disease 
by FIGO 2000 criteria, are as yet not available. In contrast to other biochemical markers, 
hCGα, hCGβ, hCG+hCGβ and the ratio of hCGβ to hCG+hCGβ, however, have shown 
to be higher in pre-evacuation blood samples in patients who developed persistent 
trophoblastic disease compared with patients who achieved spontaneous remission. 
Although the differences in the levels of these markers were significant, there was no 
predictive value for development of persistent trophoblastic disease  [16,18,28]. Our 
group previously found that hCG cut-off levels enabled early prediction of resistance to 
single-agent chemotherapy in persistent trophoblastic disease at high specificity 
[29,30].
It is reasonable to assume that in Western countries, early prediction of persistent 
trophoblastic disease  and subsequent treatment will diminish the extent of disease 
requiring less chemotherapy courses. Furthermore, chemotherapeutic treatment will 
be completed earlier, which allows earlier pregnancy in those wishing to conceive. In 
developing countries early identification of persistent trophoblastic disease will most 
likely lead to a reduction in mortality, since a high number of patients is currently 
completely lost to follow-up after evacuation and will either die or return with hardly 
curable advanced metastatic disease [31]. Identification of patients developing 
persistent trophoblastic disease  at the time of, or shortly after evacuation enables 
timely treatment of these patients. 
Chromatofocusing of glycoprotein hormones has been performed previously and 
concerned follicle stimulating hormone (FSH) and LH glycoforms. In postmenopausal 
stage, more acidic glycoforms are present and postmenopausal-like acidic FSH 
glycoforms preceded the rise of FSH before menopause [22,23]. To our knowledge, 
this is the first study that reports on predicting persistent trophoblastic disease prior to 
molar evacuation. The applied chromatofocusing technique within the group of 
glycoprotein hormones FSH, LH and hCG is a time-consuming methodology and in 
part explains the relatively low patient numbers included in these studies. Optimization 
of the present methodology can be achieved, however, by studying only those pH 
intervals that are most discriminative in persistent trophoblastic disease prediction, 
and by using larger (thus fewer) pH fractions to analyse, which leads to reduction in 
analysis time and costs. 
HCG seems to exhibit multiple direct effects on the endometrium preceding the 
endocrine effects of the hormone [32]. The degree of glycosylation of glycoprotein 
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hormones is integral to its function. The carbohydrate moiety determines biological 
activity, signal transduction as well as half-life time of the hormone in blood [21]. 
Different hCG glycoforms might therefore play an important role in the varying degrees 
of endometrial invasiveness of normal pregnancy, molar pregnancy and persistent 
trophoblastic disease. Several investigators studied the heterogeneity of the 
carbohydrate and peptide structures in circulating and secreted hCG glycoforms. 
Synthesis of hCG takes place in the syncytiotrophoblast cells while hyperglycosylated 
hCG is produced in cytotrophoblast cells in early pregnancy [33]. Comparisons of 
hCG derived from normal pregnancy, hydatidiform mole and choriocarcinoma have 
been reported by several groups [10-13,19,33,34]. The proportions of both the N- and 
O-linked glycans undergo increased branching, especially in the beta-subunits, 
progressing from normal pregnancy through hydatidiform mole to choriocarcinoma 
[19]. Lottersberger et al. showed that different pH distribution for (urinary) hCG was 
observed in malignancy (testicular choriocarcinoma) when compared with ‘normal’ 
pooled hCG from pregnancy [34]. The reason for this variance in pH distribution is that 
different hCG glycoforms are expressed due to the attached variety of terminal sialic 
acid (and/or sulphate) carbohydrate chains which in the present study is also observed 
in the case of mole pregnancy. 
In conclusion, assessment of hCG glycoform profiles in pre-evacuation serum samples 
from patients with complete hydatidiform mole can predict future development of 
persistent trophoblastic disease at 36% sensitivity with 97% specificity and further 
exploration of the present findings will result in earlier treatment of persistent 
trophoblastic disease in the initial stage of the disease. 
hcg glycoform distribution in complete hm predicts ptd
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Abstract
Objective: To determine the predictive value of pre-/postevacuation serum hCG ratios 
for persistent trophoblastic disease (PTD) obtained at different intervals after evacuation 
of hydatidiform mole compared with the current FIGO 2000 criteria for PTD. 
Methods: From 1977 to 2005 pre-/postevacuation serum hCG levels were available in 
251 cases (69 with and 182 without PTD). Receiver operating characteristic (ROC) 
curve analysis was performed to calculate Areas Under Curves (AUCs). Sensitivity and 
pre/post hCG ratios cut-off levels were calculated at 95% specificity. The numbers of 
patients predicted with PTD by pre/post hCG ratios versus the FIGO 2000 criteria were 
compared using time-specific univariate Kaplan-Maier curves and Cox’s regression 
analysis.
Results: Pre/post hCG ratios obtained in week 1 and 5 showed AUCs of 0.568 and 
0.885 respectively, and identified 6% and 64% of patients with PTD at 95% specificity, 
while with the FIGO 2000 criteria, none of the PTD patients could be identified in the 
first and 48% in the fifth week after evacuation. Significant differences were observed 
between the time of PTD diagnosis using pre/post hCG ratios and FIGO 2000 criteria 
in the first 5 weeks after evacuation (mean time for PTD prediction, 3.8 weeks; 95% CI, 
3.5-4.5) and (mean time for PTD diagnosis, 4.6 weeks; 95% CI, 4.5-4.9) respectively.
Conclusion: During the first 5 weeks after evacuation, pre/post hCG ratios identified 
patients with PTD earlier than the FIGO 2000 criteria, although validation is required to 
support this observation. Pre/post hCG ratios can be used besides the FIGO 2000 
criteria when the patient could not fully comply with the weekly postmolar serum hCG 
surveillance. 
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Introduction
Gestational trophoblastic disease (GTD) is a disease characterised by an abnormal 
proliferation of the trophoblast. It histologically includes hydatidiform mole, invasive 
mole, choriocarcinoma and placental site trophoblastic tumour. The most common 
form of GTD is molar pregnancy. There are two forms, complete and partial hydatidiform 
mole, which are diagnosed on basis of morphology, histopathology and karyotype. 
The incidence of molar pregnancy demonstrates worldwide differences, ranging from 
1 in 120-400 pregnancies in Asian countries, to 1 in 1000-2000 in Europe and the USA 
[1-3]. It is important to follow molar pregnancies after evacuation by means of serial 
serum hCG measurements because approximately 20% of complete hydatidiform 
moles and 0-3.5% of the partial moles have the potential to develop into PTD [4,5]. 
According to the widely accepted FIGO 2000 criteria the diagnosis of PTD after molar 
evacuation is based on 4 or more hCG values that show a plateau over at least 3 
weeks, or a rise in hCG levels for 2 consecutive weeks (3 or more hCG levels) [6,7]. 
These guidelines appear straightforward, but in clinical practice shortcomings do 
occur and the assessment of static or rising hCG levels is subject to personal 
interpretation of the gynaecologist in charge. In case of poor follow-up, for some 
patients clinical management needs to be based on a number of incomplete hCG 
follow-up data obtained at protracted intervals. This may occur in communities where 
regular follow-up is geographically difficult or in case of poor patient compliance.
Several studies described serum hCG regression curves for postmolar follow-up, but 
such curves are not always available to a gynaecologist, since every hCG assay requires 
a specific hCG normogram [8-10]. Serial measurement of hCG remains the most widely 
accepted method of detecting either persistence or remission of trophoblastic disease.
The objective of the present study was to evaluate whether pre-/postevacuation serum 
hCG ratios are useful for the prediction of PTD at an earlier time than with the current 
FIGO 2000 criteria. Prediction of PTD by pre/post hCG ratios would be less prone to 
inter-individual observer bias and less influenced by incomplete hCG follow-up data. 
Materials and Methods
Patients
The Dutch Central Registry for Hydatidiform Moles was established in May 1977 to 
monitor patients with GTD and to serve as a referral centre. From the start in 1977 until 
2005, 2821 patients have been registered at the Dutch Central Registry for Hydatidiform 
pre/postevacuation serum hcg ratios to predict ptd
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Moles at the Radboud University Nijmegen Medical Centre (RUNMC). We analyzed all 
patients with serum hCG data available at our RUNMC laboratory. We included those 
patients with a pre-evacuation serum hCG level- and at least one postevacuation hCG 
level available. Patients with a histopathological diagnosis of choriocarcinoma and 
patients with low level PTD (hCG < 10 ng/mL) were excluded for further analysis. Serum 
hCG data were also censored from the time chemotherapy for PTD was started. 
FIGO 2000 criteria were used to identify PTD. Patients were subdivided into two groups. 
In the present study serum hCG levels of 69 patients with proven PTD (study group) 
and 182 patients with spontaneous regression (control group) were included. For every 
patient in the study group we scored the number of weeks after evacuation at which 
PTD was diagnosed, by using the FIGO 2000 criteria and the calculated pre/post 
serum hCG ratios. 
Immunoassays
The ‘total’ hCG was measured by using an in-house developed radioimmunoassay 
(RIA). This assay detects intact hCG and free β-subunit: hCG+hCGβ (11). Based on 
this assay a  hCG regression corridor for uneventful hydatidiform moles has been 
developed previously [8]. The RIA of hCG+hCGß was calibrated with the third 
International Standard (IS) preparation for intact hCG (WHO third IS hCG 75/537 
obtained from the National Institute for Biological Standards, Potters Bar, UK). The 
measuring range for the standard line of the assay was 1-80 µg/L (0.027-2.14 nmol/L, 
equivalent to 9.29-743 IU/L of the WHO third IS hCG 75/537) [11]. For duplicate 
measurements the within- and between-assay coefficients of variation (CVw, CVb) of 
means were 7.5% and 10.3%, respectively, at a level of 10 µg/L (equivalent to 0.267 
nmol/L or 93 IU/L), and 7.3 % and 12 % respectively, at a level of 56 µg/L (equivalent to 
1.50 nmol/L or 520 IU/L).
The hCG+hCGβ-RIA cross-reacts 100% on a mol/mol basis with intact hCG and 1000% 
with hCG β-subunit. Serum hCG levels were considered to be normalized if they were 
below 2 ng/mL (0.053 nmol/L or 18.6 IU/L of the WHO third IS hCG 75/537). 
Statistics
For each patient pre/post hCG ratios were calculated by dividing the pre-evacuation serum 
hCG level by a subsequent serum hCG level obtained in week 1 through 11 after evacuation. 
The pre/post hCG ratios from week 1 through 11 were analyzed by using receiver operating 
characteristic (ROC) curves to calculate Areas Under Curves (AUCs, i.e. diagnostic 
accuracy), sensitivity and cut-off pre/post hCG ratios at 95% specificity. PTD was the only 
endpoint used in the analysis. The percentages of diagnosis of PTD in the study group, 
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either detected by the FIGO 2000 or pre/post hCG ratios, were compared using time-specific 
univariate Kaplan-Maier curves. Significant predicting factor in a univariate analysis was 
entered into a Cox’s proportional hazard model using stepwise selection to identify PTD. 
Statistical significance was defined as P < 0.05. All calculations were conducted with 
SPSS (version 14.0) for Microsoft Windows XP (SPSS, Chicago, Il, USA). 
Results
For 182 patients in the control group and 69 patients in the study group pre/post hCG 
ratios were calculated and explored by means of ROC analysis in week 1 through 11 
after evacuation. Table 1 reveals the ROC analysis of pre/post hCG ratios among the 
control group and the study group in week 1 through 11. For week 1 after evacuation, 
pre/postevacuation serum hcg ratios to predict ptd
Table 1  ROC curve analyses (AUC, sensitivity and pre/post hCG ratio cut-off 
levels at 95% specificity) from week 1 through 11 in the control and 
study group
 Week     Sensitivity Pre/post hCG
 after PTD-   PTD+     at 95 % ratio cut-off level
 evacuation n = n = AUC 95% CI  specificity (%) 
 1 122 33 0.568 0.463-0.674 12 2.7
 2 177 55 0.694 0.616-0.773 13 7.8
 3 181 51 0.750 0.695-0.855 33 21
 4 182 44 0.882 0.818-0.945 64 38
 5 167 41 0.885 0.819-0.951 63 45
 6 160 33 0.869 0.801-0.937 52 52
 7 158 26 0.871 0.795-0.946 50 154
 8 142 26 0.921 0.872-0.971 58 214
 9 123 24 0.871 0.800-0.942 46 198
 10 131 23 0.886 0.813-0.958 52 241
 11 110 18 0.878 0.799-0.957 44 264
ROC, receiver operating characteristic; AUC area under curve; hCG, human chorionic 
 gonadotropin; PTD, persistent trophoblastic disease; CI, confidence interval
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the AUC was 0.568, and the AUC increased gradually to 0.921 by week 8, after which 
a plateau occurred (AUCs ranging from 0.871 to 0.886).  In week 1, 12% of PTD patients 
could have been predicted by means of pre/post hCG ratios at 95% specificity. This 
increased to 64% sensitivity for prediction of PTD by week 4, where after sensitivity 
declined to 44 and 52% in weeks 9 through 11 respectively. 
Figure 1 shows ROC curves derived from pre/post hCG ratios of week 2, 4 and 8. 
The diagnostic accuracy (i.e. AUC) of pre/post hCG ratios increased in time up till 
week 8.
Table 2 shows the cumulative number of patients diagnosed with PTD according to the 
FIGO 2000 criteria compared with the cumulative number of patients that could have 
been predicted by pre/post hCG ratios. At week 1 pre/post hCG ratios allowed 
prediction of 4 patients (6%) while FIGO 2000 criteria did not identify any patient with 
PTD. In week 2, 9 patients (13%) with PTD were detected by means of pre/post hCG 
ratios from study group compared to 1 (1%) with the FIGO 2000 criteria. 
chapter 6
Figure 1  Receiver operating characteristics curves for pre/post hCG ratios when 
used among the control group and the study group in week 2, 4 and 8 
after evacuation 
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In the first 5 weeks after evacuation pre/post hCG ratios predicted a cumulative 
percentage of 64% of patients who developed PTD, whereas the FIGO 2000 criteria 
only identified 48% of patients. By week 7 after evacuation, both FIGO 2000 criteria and 
pre/post hCG ratios identified approximately 75% of PTD patients.
Figure 2 shows the Kaplan-Maier curves of patients with PTD as predicted by pre/post 
hCG ratios compared to those diagnosed by the FIGO 2000 criteria, sorted per week 
after evacuation. 
Kaplan-Maier analysis demonstrated a significant difference between the pre/post 
hCG ratios and FIGO 2000 criteria in the first 5 weeks after evacuation: pre/post hCG 
ratios (mean time for PTD prediction, 3.8 weeks; 95% confidence interval, 3.5-4.5) and 
FIGO 2000 criteria (mean time for PTD diagnosis, 4.6 weeks; 95% confidence interval, 
4.5-4.9). 
chapter 6
Figure 2  Kaplan-Maier curves of patients with PTD as predicted by pre/post 
hCG ratios (+) and diagnosed by the FIGO 2000 criteria (O) during  
the first 5 weeks after evacuation  
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Discussion
Previously Van Trommel et al. have shown earlier detection of PTD by means of serum 
hCG ratios obtained after evacuation, when compared with the current widely accepted 
FIGO 2000 criteria [12, 13]. In the present study we have explored the predictive value 
of pre-/postevacuation hCG ratios for prediction of PTD between week 1 through 11 
after molar evacuation. The findings of the present study suggest that pre/post hCG 
ratios can predict PTD at an earlier stage in comparison with the FIGO 2000 criteria. 
Furthermore, pre/post hCG ratios can be useful at typical clinical scenarios when 
patients could not fully comply with the weekly postmolar hCG surveillance. A single 
pre-evacuation serum hCG level and one postevacuation level might be sufficient to 
predict PTD.
At week 1 pre/post hCG ratios could already distinguish 4 patients (6%) who will 
eventually develop PTD while the FIGO 2000 criteria did not allow diagnosis of any 
patient with PTD in the study group. At week 5 pre/post hCG ratios predicted 44 
patients (64%) in comparison with 15 patients (48%) diagnosed with PTD by the FIGO 
2000 criteria. In the first 5 weeks after evacuation pre/post hCG ratios predicted 
significantly (P = 0.03) more patients who eventually developed PTD in comparison 
with the FIGO 2000 criteria. Several authors have attempted to quantify the diagnosis 
of PTD by using serum hCG regression curves for hCG follow-up after molar evacuation 
[8-10]. A worldwide introduction of these regression curves is impractical, since each 
hCG assay will require a specific curve as hCG assays differ in terms of analytic 
specificity and sensitivity. Up to date, researchers were not able to develop a 
biochemical or clinical tool to identify PTD at an earlier stage than the current FIGO 
2000 criteria. Serial hCG measurement remains the most reliable method to predict 
either persistence or remission. In 2002, FIGO updated its guidelines for the definition 
of PTD [13]. Following these criteria PTD is diagnosed in case of a plateau for four 
weekly measurements or a rise in hCG levels during 3 weekly measurements. Weekly 
measurement of serum hCG levels requires high patient compliance, which is 
mandatory to diagnose PTD according the FIGO 2000 criteria. High rates of 
non-compliance with postmolar surveillance might lead to delayed diagnosis. 
The frequency of the hCG follow-up is determined by the quality of information provided 
by the gynecologist, the available resources for hCG measurement and the individual 
patient’s compliance. Poverty and patient apathy pose potential obstacles to weekly 
postmolar hCG surveillance [14, 15]. Simplifying strategies could encompass 
compliance. Massad et al. showed in their study poor patient compliance in postmolar 
surveillance [14]. Only 47% of the patients of their study group complied fully with 
pre/postevacuation serum hcg ratios to predict ptd
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protocols for both follow-up and treatment. In the study of Allen et al. a minority of 
cases (31%) complied with postmolar hCG surveillance [15]. At the New England 
Trophoblastic Disease Center 2.8% of the patients were lost to follow-up before 
achieving remission and 38.5% of the patients were lost prior to completing follow-up 
[16]. Kim et al. described noncompliance in their study of prophylactic chemotherapy 
after molar pregnancy [17].  Early administration of chemotherapy did not increase 
likelihood of cure. However they suggest that simplifying the present post molar 
surveillance could enhance compliance.
In the Netherlands patients are registered at the Central Registry for Hydatidiform 
Moles at the RUNMC by their referring gynaecologists. The continued success of the 
national surveillance protocol has ensured that the majority of patients requiring 
chemotherapy for PTD are identified at an early stage. Using the FIGO 2000 criteria, 
the follow-up period could sometimes be lengthy, requiring weeks or months to 
diagnose PTD. With this in mind, we developed a simple and practical model to predict 
PTD at an earlier stage. The relevance of this method remains to be elucidated in 
standard clinical practice. Pre/post hCG ratios can be used in addition to the FIGO 
2000 criteria at typical clinical scenarios when the patient cannot fully comply with the 
weekly postmolar pregnancy hCG surveillance. Pre/post hCG ratios may allow clinicians 
to perform risk stratification of their patients with a molar pregnancy during the initial 
weeks after evacuation and may provide a tool for more individual counseling. 
In conclusion, by using this newly established study model of pre/post hCG ratios we 
identified patients with PTD earlier than based on a plateau or rise in weekly hCG 
values according to the FIGO 2000 criteria in the first 5 weeks after evacuation. The 
findings of the present study need to be validated prospectively, although the FIGO 
2000 criteria should remain to be the gold standard in diagnosing PTD.
chapter 6
103
6
References
 1. Bracken MB. Incidence and aetiology of hydatidiform mole; an epidemiological review. Br J Obstet 
Gynaecol 1987;94:1123-1135
 2. Steigrad SJ. Epidemiology of gestational trophoblastic diseases. Best Pract Res Clin Obstet 
Gynaecol 2003;17:837-847 
 3. Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med 
1994;39:155-162
 4. Lurain JR, Brewer JI, Torok EE, Halpern B. Natural history of hydatidiform mole after primary 
evacuation. Am J Obstet Gynecol 1983;145:591-595
 5. Lawler SD, Fisher RA, Dent J. A prospective genetic study of complete and partial hydatidiform 
moles. Am J Obstet Gynecol 1991;164:1270-1277
 6. FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J 
Gynaecol Obstet 2002;77:285-287
 7. Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic 
disease: description and critical assessment. Int J Gynecol Cancer 2001;11:73-77
 8. Yedema KA, Verheijen RH, Kenemans P, Schijf CP, Borm GF, Segers MF et al. Identification of patients 
with persistent trophoblastic disease by means of a normal human chorionic gonadotropin 
regression curve. Am J Obstet Gynecol 1993;168:787-792
 9. Shigematsu T, Kamura T, Saito T, Kaku T, Nakano H, Kinugawa N. Identification of persistent 
trophoblastic diseases based on a human chorionic gonadotropin regression curve by means of 
a stepwise piecewise linear regression analysis after the evacuation of uneventful moles. Gynecol 
Oncol 1998;71:376-380
 10. Behtash N, Ghaemmaghami F, Honar H, Riazi K, Nori A, Modares M, Mousavi A. Is normal beta-hCG 
regression curve helpful in the diagnosis of persistent trophoblastic disease? Int J Gynecol Cancer 
2004;14:980-983
 11. Thomas CM, Segers MF, Houx PC: Comparison of the analytical characteristics and clinical 
usefulness in tumour monitoring of fifteen hCG(-beta) immunoassay kits. Ann Clin Biochem 
1985;22:236-246
 12. van Trommel NE, Ngo Duc H, Massuger LF, Schijf CP, Sweep CG, Thomas CM, et al. Early identification 
of persistent trophoblastic disease with serum hCG concentration ratios. Int J Gynecol Cancer 
2008;18:318-323
 13. Ngan HY. The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. Int J 
Gynecol Cancer 2004;14:202-205
 14. Massad LS, Abu-Rustum NR, Lee SS, Renta V. Poor compliance with postmolar surveillance and 
treatment protocols by indigent women. Obstet Gynecol 2000;96:940-944
 15. Allen JE, King MR, Farrar DF, Miller DS, Schorge JO. Postmolar surveillance at a trophoblastic 
disease center that serves indigent women. Am J Obstet Gynecol 2003;188:1151-1153
 16. Wolfberg AJ, Feltmate C, Goldstein DP, Berkowitz RS, Lieberman E. Low risk of relapse after achieving 
undetectable HCG levels in women with complete molar pregnancy. Obstet Gynecol 2004;104:551-554
 17. Kim DS, Moon H, Kim KT, Moon YJ, Hwang YY. Effects of prophylactic chemotherapy for persistent 
trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol 
1986;67:690-694
pre/postevacuation serum hcg ratios to predict ptd

1CHAPTER
4CHAPTER
5CHAPTER
6CHAPTER
2CHAPTER
3CHAPTER
7CHAPTER
8CHAPTER
External validation of serum hCG cut-off  
levels for prediction of resistance to single-agent 
 chemotherapy in patients with persistent  
trophoblastic disease
Linda GW Kerkmeijer, Chris MG Thomas, Richard A Harvey, 
Hugh D Mitchell, Fred CGJ Sweep, Leon FAG Massuger, Michael J Seckl
British Journal of Cancer 2009; 100: 979-984
106
Abstract
Objective: Van Trommel et al. have previously shown that serum human chorionic 
gonadotropin (hCG) cutoff levels can provide early prediction of resistance to first-line 
methotrexate (MTX) in patients with persistent trophoblastic disease (PTD). In this 
study, we validate this approach of prediction of resistance to single-agent 
chemotherapy in an independent and larger cohort of PTD patients using a different 
hCG assay. 
Methods: Receiver operating characteristics (ROC) curves were constructed to 
determine hCG cutoff levels and sensitivity between patients cured on single-agent 
chemotherapy (control group) and patients requiring change to combination 
chemotherapy (study group). 
Results: Receiver operating characteristics analysis identified an hCG cutoff value of 
737 IU /L that enabled us to predict the subsequent development of single-agent 
chemotherapy resistance in 52% of patients before their fourth MTX course at 97.5% 
specificity. This would have enabled an earlier switch to combination chemotherapy 
reducing the MTX exposure by an average of 2.5 courses. 
Conclusion: The present findings confirm that serum hCG cutoff levels predict 
resistance to single-agent therapy earlier than traditional methods. Change to 
combination chemotherapy should be considered for patients whose serum hCG 
levels exceed these hCG cutoff values. For patients not exceeding the hCG cutoff 
levels, static or rising hCG levels should still be included in the criteria for change of 
chemotherapy.
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Introduction 
Human chorionic gonadotropin (hCG) is a sensitive marker in monitoring trophoblastic 
activity in gestational trophoblastic disease (GTD) [1]. Persistent trophoblastic disease 
(PTD) is a clinical diagnosis, based on static or rising hCG levels following uterine 
evacuation of hydatidiform mole. The International Federation of Gynecology and 
Obstetrics (FIGO) defines PTD as static hCG levels in four consecutive blood samples, 
a rising hCG concentration in three consecutive samples or persistence of elevated 
hCG levels for more than 6 months after evacuation [2]. Persistent trophoblastic 
disease occurs most commonly after complete hydatidiform moles (15%), although 
partial hydatidiform moles may also transform into malignant GTD (0.5%) [3,4]. 
Depending on their prognostic risk category, patients are generally treated with first-line 
single-agent chemotherapy (methotrexate (MTX) or actinomycin D) in case of low-risk 
disease or first-line EMA/CO combination chemotherapy (etoposide, MTX, actinomycin 
D, cyclophosphamide and oncovin) in case of high-risk PTD [2]. Furthermore, 17–36% 
of patients initially treated with low-risk MTX require a change of chemotherapy due to 
MTX resistance. To date, the most widely used marker for resistance to single-agent 
chemotherapy is a plateau or rise in serum hCG levels, which can obviously occur after 
several courses of treatment [5-8]. Consequently, earlier detection of patients likely to 
develop resistance is desirable, so that more appropriate therapy can be given to cure 
the disease rapidly.
Recent work from Van Trommel et al [9] has identified serum hCG cutoff points, that 
allowed early prediction of MTX resistance. This study was based on hCG levels of 79 
patients cured by first-line MTX. At 97.5% specificity, 50% of low-risk PTD patients not 
responding to MTX (n=29) could be identified just before the start of the fourth MTX 
course. Previously, Rotmensch et al [10] designed a 90th percentile log-exponential 
regression curve with hCG levels of 19 patients successfully treated with MTX. Other 
investigators suggested hCG cutoff points determined by ROC curves for identifying 
MTX refractory patients based on hCG regression in MTX responsive patients [11]. 
Prolonged duration of chemotherapy due to belated identification of single-agent 
refractory disease will likely increase stress levels and adversely affect quality of life 
because the total duration of therapy is increased. Although early detection of patients 
unresponsive to single-agent therapy is favourable, hCG cutoff levels to identify 
resistant disease should be stringent, as starting unnecessary high-risk chemotherapy 
might elicit severe toxicities and advance menopause [12,13]. Further validation of the 
study performed by Van Trommel et al [9] on serum hCG cutoff levels as a predictor for 
resistance to single-agent chemotherapy (developmental study) is required before 
prediction of resistance to single-agent chemotherapy in ptd
108
clinical implementation. Therefore, the purpose of this study is to validate and extend 
the findings obtained from the Dutch developmental study on prediction of the need for 
combination chemotherapy in a larger external British patient cohort, in a different 
clinical setting, with serum hCG values obtained using a different hCG radio-
immunoassay (RIA) in an independent laboratory.
Materials and methods
Study population and setting
Charing Cross Hospital, London, is one of the two centres in the United Kingdom for 
treatment of GTD. Between August 1993 and October 2007, 782 patients were treated with 
first-line MTX chemotherapy for low-risk PTD at Charing Cross Hospital. Exclusion criteria 
for further analysis are shown in Figure 1. A total of 655 patients with low-risk PTD, initially 
treated with single-agent chemotherapy, were included retrospectively in this study. 
Patients with an FIGO 2000 prognostic score ≤ 6 [2] were instituted on first-line single-agent 
MTX hemotherapy with folinic acid rescue (50 mg intramuscular MTX on days 1, 3, 5 and 
7 with folinic acid 30mg orally on days 2, 4, 6 and 8, repeated every 2 weeks). Single-agent 
chemotherapy drug resistance was defined as two static or rising hCG levels (study end 
point). In the United Kingdom, for patients resistant to MTX, treatment was converted to 
second-line chemotherapy according to their hCG level, which is known to be associated 
with the amount of remaining trophoblastic tissue. Patients with MTX refractory disease are 
treated with second-line single-agent actinomycin D (hCG ≤ 100 IU/L) or second-line 
combination chemotherapy (EMA/CO) in case of hCG levels > 100 IU/L at the time of 
development of MTX resistance. A more reserved attitude towards treatment with 
combination chemotherapy has been introduced recently (hCG > 100 IU/L recently 
became > 300 IU/L for treatment with combination chemotherapy). This may increase the 
number of patients cured on single-agent chemotherapy. Actinomycin D (0.5 mg on days 
1–5, repeated every 2 weeks) has shown to be a successful single-agent therapy for MTX 
resistant PTD, and did not compromise longterm outcome in patients subsequently 
requiring third-line combination chemotherapy [7]. Following normalisation of serum hCG 
levels (< 5 IU/L), treatment was continued for another 6 weeks (three consolidation 
courses), where after lifelong follow-up of hCG levels proceeded. Low-risk patients with 
pulmonary metastasis on chest X-ray received central nervous system prophylaxis with 
intrathecal MTX (MTX-IT) in addition to the first-line systemic MTX for possible occult 
cerebral metastases. Those patients were excluded from further analysis, as the additional 
effect of intrathecal MTX on systemic hCG levels is unknown. 
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Immunoassays
In the United Kingdom, a non-commercial one-site in-house competitive hCG RIA 
using a rabbit polyclonal antibody is utilized for monitoring GTD. The antibody used in 
this RIA is directed to an epitope on the β-subunit and detects all known forms of 
β-hCG including free β, intact hCG and β-core fragment with a comparable cross- 
reactivity for the different forms of serum hCG. Furthermore, the antibody is not affected 
by nicked hCG and cross-reacts less than 0.25% with luteinising hormone of pituitary 
origin. The analytical sensitivity of the assay is 1 IU/L. Human chorionic gonadotropin 
levels less than 5 IU/L are considered normal [14].
Statistical methods
Statistical analyses were performed using the SPSS statistical software package for 
Microsoft Windows (version 14.0, SPSS Inc, Chicago, IL, USA). Serum hCG levels were 
sorted within each MTX chemotherapy course number and data were excluded for 
further analysis from the moment therapy other than MTX started (hysterectomy, 
second curettage and second-line chemotherapy).
Normalities of distributions were explored by means of the Kolmogorov–Smirnov test. 
Individual serum hCG levels were not normally distributed, neither with transformations. 
Therefore, we performed a non-parametrical analysis by means of ROC curves to 
determine hCG cutoff levels (decision threshold) for prediction of the need for 
combination chemotherapy (preceding each MTX course) at 99% specificity. Receiver 
operating characteristics curves were obtained from individual serum hCG levels 
grouped by MTX course to determine hCG cutoff levels (at 97.5 and 99% specificity), 
sensitivity (ie, percentage of patients identified) and area under curve (AUC). As 
sensitivity for prediction of the need for combination chemotherapy was dependent on 
the specificity level chosen and the AUC was not, we considered sensitivity to be the 
most important outcome measure. To make the results more accessible, we converted 
the absolute hCG levels given in IU/L also in percent rates of hCG serum levels. The 
conversion is based on 100% = 23667 IU/L, that is, the median (p50) hCG level of the 
study group before the first MTX course. Differences in numerical parametrical data 
were calculated by means of the two-tailed Student’s t-test. Non-parametrical data 
were assessed by the use of the two-tailed Mann–Whitney U-test. P-values less than 
0.05 were considered statistically significant. In case of patients < 30 in numbers, data 
were censored.
prediction of resistance to single-agent chemotherapy in ptd
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Results
A total of 782 patients received single-agent chemotherapy for low-risk PTD. Six 
hundred and fifty-five patients with low-risk persistent disease treated with single-agent 
chemotherapy between August 1993 and October 2007 fulfilled the inclusion criteria 
shown in Figure 1.
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Exclusion criteria: 
* Non-molar abortion * Exaggerated placental  
* Ectopic pregnancy        site reaction 
* Twin pregnancy  * Placent al site trophoblastic    
* Hydropic abortion     tumour   
   n = 26 
        
 
    
 
Study group  
n = 166 (25%) 
 
* CHM: n = 132 
* PHM: n = 13 
* Unclassified HM: n = 21 
Patients initially treated with MTX  
FIGO 2000 score  ≤ 6 
Charing Cross Hospital 1993-2007 
N = 782 
Low-risk PTD following hydatidiform 
mole receiving first-line MTX 
chemotherapy 
n = 756 
Exclusion criteria: 
* hCG data not available  * Second curettage  
* Patients with only hCG levels * MTX -IT  
 < 5 IU/L * < 3 MTX courses in  
* Recurrent disease following     control group 
  initial hCG normalization on MTX   n = 101 
 
Control group 
n = 489 (75%) 
 
* CHM: n = 386 
* PHM: n = 52 
* Unclassified HM n = 51 
Patients requiring 
combination 
chemotherapy  
 
n = 166 
MTX resistance 
hCG > 100 IU/L 
 
EMA/CO 
 (including previous  
Act. D  n = 16) 
 
 
 
 
MTX resistance 
hCG < 100 IU/L 
 
Second-line Act. D: 
hCG normalisation 
n = 92 
 
 
 
 
 
 
First-line MTX:  
hCG normalisation 
 
n = 397 
 
Patients responding  
to single-agent 
chemotherapy 
 
n = 489 
Figure 1  Flow-chart of inclusion criteria of patients initially treated with 
 single-agent MTX 
Abbreviations: MTX= methotrexate, FIGO= International Federation of Gynecology and Obstetrics, 
PTD= persistent trophoblastic disease, hCG= human chorionic gonadotropin, act. D= actinomycin 
D, EMA/CO= etoposide, MTX, actinomycin D, cyclophosphamide, oncovin, CHM= complete 
hydatidiform mole, PHM= partial hydatidiform mole, MTX-IT= intra-thecal MTX
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Four hundred and eighty-nine patients (75%, control group) attained remission of 
trophoblastic disease on single-agent chemotherapy alone and 166 patients (25%, 
study group) required change to a combination chemotherapy regimen due to 
single-agent therapy resistance. Among the 489 patients who achieved remission on 
single-agent chemotherapy, 92 patients (18%) achieved remission on second-line 
single-agent actinomycin D following MTX chemotherapy. One hundred and sixty-six 
patients required combination chemotherapy, including 16 patients (10%) who previously 
received second-line actinomycin D following MTX chemotherapy. Table 1 describes 
clinical and therapy-related characteristics of patients initially treated with single-agent 
chemotherapy. In the case of 48 and 19 patients in the control and study group, 
respectively, evacuation dates were not available in the registry’s database. Those 
patients were not eligible for the analysis of maternal age and start date of single-agent 
chemotherapy. Maternal ages at the time of evacuation did not differ comparing the 
prediction of resistance to single-agent chemotherapy in ptd
Table 1  Clinical and therapeutic features of patients initially treated with 
MTX chemotherapy 
Diagnosis     Control group Study group 
  n = 489 n = 166 p
Maternal age (years)
 Median (range) 30 (18-46) 31 (21-45) NS†
Start MTX (wks after evacuation)
 Median (range) 10 (4-27) 7 (3-31) < 0.0001†
Pre-chemotherapy hCG (IU/L)
 Median (range) 4614 (50-5.8*104) 23667 (638-1.8*105) < 0.0001†
Number of courses MTX
 Median (range) 6 (3-10) 4 (2-6) < 0.0001†
Number of courses actinomycin D
 Median (range) 5 (1-7) 2 (1-5) NA
Number of courses EMA/CO
 Median (range) NA 5 (2-11) NA
Abbreviations: MTX= methotrexate, hCG= human chorionic gonadotropin, EMA/CO= etoposide, 
MTX, actinomycin D, cyclophosphamide, oncovin, NS= not significant, NA= not applicable,  
† Mann-Whitney U test, Range= 5th to 95th percentile
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control group with the study group. However, start date of MTX chemotherapy was 
significantly further from evacuation in the control group when compared with the study 
group (median 10 vs 7 weeks, P<0.0001). Overall, for 95% of patients, the firstline MTX 
was administered within 26 weeks from evacuation. As expected, prechemotherapy 
hCG levels were statistically lower in the control group than in the study group (median 
4614 IU/L = 19% vs 23667 IU/L = 100%, P<0.0001). Individuals from the control group 
received significantly more MTX courses than those among the study group (median, 
six vs four courses, P<0.0001). The number of patients that received second-line 
actinomycin D in the study group (n = 16, median, two courses) was too low to be 
compared with the patients that received secondline actinomycin D in the control group 
(n = 92, median five courses). The median number of courses EMA/CO combination 
chemotherapy for patients in the study group was five. 
Table 2 shows the non-parametric assessment of hCG cutoff levels by means of ROC 
curves (represented in Figure 2) derived from serum hCG levels from patients who 
gained cure on single-agent therapy compared with those who required combination 
chemotherapy, sorted per MTX course number. 
We evaluated hCG cutoff levels and sensitivity both at the 97.5 and 99% specificity 
level. Before the start of MTX chemotherapy, 19% of patients eventually requiring 
combination chemotherapy could have been identified by means of hCG cutoff levels 
(hCG cutoff: 57315 IU/L = 242%), whereas before the fourth course, sensitivity 
increased to 52% (hCG cutoff: 737 IU/L = 3%) at 97.5% specificity. When using the 
more strict 99% specificity level to prevent unnecessary change to combination 
chemotherapy, sensitivity decreased, whereas hCG cutoff levels increased. Before the 
start of the first MTX course (hCG cutoff: 121664 IU/L = 514%), 9% of all MTX-resistant 
patients could be predicted at 99% specificity. This percentage increased to 26% 
before the fourth course (hCG cutoff: 1580 IU/L = 7%). Moreover, for single-agent 
chemotherapy-resistant PTD with hCG levels exceeding one or more hCG cutoff levels 
before the first, second, third, fourth or fifth MTX course at 97.5% specificity, the number 
of MTX chemotherapy courses could have been reduced, in retrospect, by an average 
of 2.5 MTX courses (range, 1–9 courses). In case the hCG cutoff levels at 99% specificity 
would have been applied, an average of 2.1 MTX courses (range, 1–6) could have 
been saved. These data are not shown in Table 2. 
Figure 3 illustrates hCG cutoff levels derived from ROC analysis based on serum hCG 
regression in the study group, when compared with the hCG levels among the control 
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group. For patients with hCG levels in the dark grey area, the need for combination 
chemotherapy could be predicted by means of exceeding the hCG cutoff levels when 
specificity was set at 99%. Patients with hCG levels in the medium grey area could 
additionally be identified in case hCG cutoff levels at 97.5% specificity would have 
been applied. Patients with hCG levels in the light grey area could not be predicted by 
exceeding of the hCG cutoff levels at 97.5 or 99% specificity. In addition to absolute 
hCG levels, the Y-axis shows the hCG levels converted to percent rates, based on 
100% = 23667 IU/L, that is, the median of serum hCG levels among the study group 
before the first MTX course.
chapter 7
Figure 2  Receiver operating characteristics curves of serum hCG levels in 
patients requiring combination chemotherapy (study group) compared 
with hCG levels among the patients cured on single-agent chemo-
therapy (control group) before the first, third, fourth and fifth MTX 
course (MTX 1, 3, 4 and 5) 
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Discussion
The purpose of this study was to validate the Dutch developmental study on prediction 
of the need for combination chemotherapy by means of hCG cutoff levels performed 
by Van Trommel et al [9] using a much larger retrospective PTD patient data set from a 
different organisation with a distinct hCG assay. A six times larger patient number in 
the present validation study enabled us to refine the model for determining hCG cutoff 
levels as developed earlier by Van Trommel et al [9]. First, to reduce the false positive 
diagnosis of single-agent chemotherapy resistance, we calculated the specificity level 
at 99% in addition to the 97.5% specificity level. A further adjustment of the calculations 
performed by Van Trommel et al [9] was the removal of all hCG levels from the moment 
prediction of resistance to single-agent chemotherapy in ptd
Figure 3  Serum hCG regression in patients requiring combination chemo-
therapy (study group) compared with serum hCG cutoff levels at  
99 and 97.5% specificity based on ROC analysis of hCG levels among 
the study vs the control group
Abbreviations: hCG= human chorionic gonadotropin, MTX= methotrexate
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of hCG normalisation in the control group. This is because, in the prospective setting, 
patients who achieve normalisation are not considered for further treatment. 
Consequently, hCG cutoff levels increased, and there was a slight decrease in the 
calculated predictive value for MTX resistance relative to that of a calculation including 
all normal hCG levels. The last refinement in the model for determining hCG cutoff 
levels for prediction of MTX resistance is that we have calculated those hCG cutoff 
levels by non-parametric analysis only, as the present serum hCG data were not 
normally distributed, whereas Van Trommel et al [9] used both parametric (log-
transformed hCG regression lines) and non-parametric assessment (derived from 
ROC analysis). One-fourth of all patients initially treated for low-risk PTD with 
single-agent chemotherapy subsequently required combination chemotherapy. For 
those patients requiring combination chemotherapy, serum hCG cutoff levels could 
predict 26% of single-agent chemotherapy-resistant patients before the fourth MTX 
course at 99% specificity. Interestingly, a 1.5% decrease in specificity (from 99 to 
97.5%) gives rise to a two times higher sensitivity (from 26 to 52%), although earlier 
identification of patients requiring combination chemotherapy at the expense of a 
decrease in specificity (ie, false-positive diagnosis of single-agent chemotherapy 
refractory disease) is unfavourable. For MTX refractory patients with one or more serum 
hCG levels exceeding the hCG cutoff levels before the first, second, third, fourth or fifth 
MTX course at 97.5% specificity, the number of MTX chemotherapy courses could 
have been reduced, in retrospect, by an average of 2.5 courses (range 1–9). 
Comparison of absolute hCG cutoff levels of this study with hCG cutoff levels derived 
from the developmental study of Van Trommel et al [9] is not applicable, as a different 
RIA was used, with different sensitivity, specificity and cross-reactivity. Confirmatory 
data using a distinct much larger patient cohort with another RIA of course further 
strengthens our model. Using hCG cutoff levels at 97.5% specificity, we found that 52% 
of patients resistant to single-agent chemotherapy could be identified before the fourth 
MTX course, which is comparable to 50% of MTX-resistant patients predictable in the 
Dutch developmental study. The percentage of MTXresistant patients identified by 
means of hCG cutoff levels might be influenced by the low number of MTX-resistant 
patients in the Dutch cohort (n = 29) and a 10 times higher cross-reactivity for β-hCG 
in the Dutch assay, which may overestimate the difference in hCG levels between MTX 
responsive and resistant patients and the method of assessment of hCG cutoff levels. 
Also, in this study,  the control group consisted of patients cured on single-agent 
chemotherapy (including MTX and actinomycin D), whereas the control group in the 
developmental study consisted of patients cured on MTX solely. The serum hCG levels 
among the subgroup who received MTX-only were comparable to those observed in 
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the total single-agent chemotherapy group. The higher median number of MTX courses 
in the Dutch group than in the Charing Cross group of patients eventually requiring 
combination chemotherapy (seven vs four courses of first-line MTX) suggest a more 
proactive approach towards change to combination therapy in the latter. Prospective 
testing of a parameter on an independent set of patients in a multicentre setting is the 
ultimate test a parameter has to go through before reaching the level of evidence (LOE) 
type I according to the Tumor Marker Utility Grading Scale as introduced by Hayes et 
al [15]. Because of the retrospective nature of our external validation study, we 
considered the LOE to be III out of V. Unfortunately, a prospective study is impracticable, 
as low-risk PTD is a rare condition. Confounding factors due to the retrospective nature 
of this study were for instance different criteria for low-risk disease in force at the time. 
However, MTX treatment protocols and criteria for MTX resistance did not diverge 
within this study, enabled by centralised treatment of PTD at one specialized centre. 
Although LOE type I is not reached, we consider our parameter suitable for the 
application in the routine clinical practice. In this study, 39% of patients initially classified 
as low-risk PTD, developed resistance to MTX, an apparent increase compared with 
resistance rates reported by the Charing Cross Hospital before (1989: 20%, 2002: 
31%) [7,16]. In 1989, patients were classified as low-risk PTD with a Charing Cross 
score from 0 to 5 (≤ 8 corresponds to an FIGO score ≤ 6) [16]. The subsequent 
inclusion of the former medium risk group of patients scoring 6–8 on the Charing Cross 
Score likely accounts for the increased MTX resistance was seen. Indeed, the report 
from 2002 included several patients who were classified as low-risk PTD with a Charing 
Cross score between 0 and 8 [7]. This study incorporated more patients who were 
classified as low-risk PTD by the revised classification, resulting in a higher proportion 
of higher prognostic risk scores, and thus an increased MTX resistance rate. In 
conclusion, we confirm the earlier observation by Van Trommel et al [9] that hCG cutoff 
levels are useful for the prediction of resistance to single-agent chemotherapy. Change 
to combination chemotherapy should be considered for patients whose serum hCG 
levels exceed the cutoff levels. For patients not exceeding the hCG cutoff levels, static 
or rising hCG levels should still be included in the criteria for change of chemothera-
peutic regimen following single-agent chemotherapy. Our model of prediction of the 
need for combination chemotherapy proved to be valid on an independent group of 
patients with hCG values obtained using a different hCG assay.
prediction of resistance to single-agent chemotherapy in ptd
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General Discussion
Before the development of sensitive assays for hCG and the availability of effective 
chemotherapeutic treatment, mortality was substantial for all forms of GTN. Today it is 
one of the most curable forms of malignancy, even in the presence of metastatic disease. 
The high cure rates can only be achieved provided that detection and adequate treatment 
is performed in an early stage of the disease and that  follow-up is guided by extensive 
hCG monitoring. However, currently this extensive monitoring takes  a lengthy follow-up 
period. In HM patients not at risk of developing PTD the follow-up period should be 
shortened. In an attempt to optimize the current follow-up protocol and improve the early 
detection of PTD, several studies were performed in the framework of the present thesis 
that examined the prediction and follow-up of GTD, PTD in particular. In this thesis serum 
hCG regression in uneventful complete HM before and after the institution of routine first 
trimester ultrasonography in the Netherlands is evaluated (Chapter 2). Subsequently, 
observations on the incidence of recurrent trophoblastic disease following spontaneous 
normalization of hCG levels in hydatidiform mole are described (Chapters 3 and 4). For 
the prediction of PTD in complete HM, we assessed the hCG glycoform distribution 
patterns obtained by chromatofocusing of a blood sample collected prior to molar 
evacuation (Chapter 5). We also examined the value of pre-/post-evacuation hCG 
concentration ratios in predicting PTD after evacuation of the molar tissue  (Chapter 6). 
Finally, we performed an external validation study of our previous observation that hCG 
levels allow early prediction of single-agent chemotherapy resistance in patients initially 
diagnosed with low-risk PTD (Chapter 7).  
Do FIGO criteria need to be changed as a result of earlier ultrasound 
detection of HM?
Nowadays, most complete HM are diagnosed in the first trimester of pregnancy. As a 
consequence pre-evacuation hCG levels and time to hCG normalization are lower due to 
the earlier detection and evacuation of complete molar pregnancy in the last fifteen 
years. Ninety-nine percent of the recent cohort of complete HM (1994 to 2006) achieved 
hCG normalization within 19 weeks after molar evacuation compared with 25 weeks in 
the historic group (1977 to 1989). Apart from a rise or plateau in hCG levels, FIGO criteria 
describe that PTD can also be diagnosed based on elevated hCG levels at 6 months 
after evacuation. As complete moles not developing PTD achieve hCG normalisation 
earlier in recent years, the latter FIGO criterion may no longer be adequate for diagnosis 
of PTD. In order to investigate whether the present FIGO criteria need to be changed, it 
should be examined how often PTD is diagnosed based on the criterion of elevated hCG 
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levels at 6 months after evacuation and whether advancing this criterion for diagnosis of 
PTD would influence treatment outcome. Unfortunately, earlier detection and evacuation 
of HM in recent years did not lead to decreased incidence of PTD [13].  
Can hCG follow-up safely be discontinued after normalization of  
hCG levels in HM?
Previous studies suggested that the period of follow-up after normalization of hCG levels 
may be shortened, since the risk of developing recurrent GTD is extremely low [1-12]. 
The present thesis describes two studies conducted among HM patients with 
spontaneous hCG normalization. The first one, performed in Victoria, Australia, revealed 
that none of the 287 patients with complete HM developed relapse of trophoblastic 
disease once two or more hCG levels below the normal cut-off level of the used assay 
were obtained. The second study, carried out in the Netherlands, showed that among 
265 patients with spontaneous hCG normalisation one patient (0.38%) subsequently 
required chemotherapeutic treatment for recurrent trophoblastic disease after hCG had 
been below the normal cut-off level for two consecutive measurements. To our knowledge, 
so far, a total of 13 studies have been carried out dealing with the risk of recurrent GTD 
following spontaneous normalization of hCG levels. The patients included in these 
studies had been diagnosed between 1963 and 2006. The risk of recurrent GTD after 
uneventful HM appeared to be extremely low; 33 out of 14,215 patients (i.e. 1:431) as 
found in an unselected group of HM patients including both complete and partial HM. 
Most cases of recurrent GTD occurred more than 15 years ago, when hCG assays used 
generally had a higher detection limit than the assays used nowadays. Thus, it is logical 
to assume that the incidence rates of recurrent GTD following two hCG levels below 
normal cut-off level in uneventful HM are  lower in recent years. Recently, the Dutch 
Society for Obstetrics and Gynecology revised the guidelines specifically for follow-up of 
partial HM, advocating discontinuation of hCG follow-up after hCG normalisation. In our 
opinion either a central pathological review diagnosis of all cases of HM or standard 
flowcytometric analysis should be performed to minimize misclassification of the mole. 
However, we are convinced that besides the abrogation of follow-up for uneventful partial 
HM, as implemented by the Dutch Society for Obstetrics and Gynecology, the follow-up 
for complete HM can also be discontinued after achieving two weekly hCG levels below 
the normal cut-off level.
Can we predict PTD at time of molar evacuation?
Our retrospective study was the first that showed that a proportion of HM patients 
eventually developing PTD could have been predicted prior to molar evacuation. 
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Previously progesterone, inhibin A, activin A, human placental lactogen, CA-125, CEA, 
CA 15-3, CA 19-9, leptin, 17 β-estradiol, hCG β-subunit, nicked hCG, hCG β core 
fragment, hyperglycosylated hCG and intact hCG showed no clinical benefit for early 
prediction of PTD in HM [14-26]. In the present thesis, hCG glycoform patterns were 
studied for their predictive value for developing PTD in complete HM. Assessment of 
hCG glycoform profiles by chromatofocusing of hCG (pI 6.3-5.1) in pre-evacuation serum 
samples from patients with complete HM can predict future development of PTD at 
sensitivity rates of 36% at 97% specificity. Before clinical application, the value of  hCG 
glycosylation profile for the prediction of PTD should be validated in a larger group of HM 
patients. The time-consuming method of chromatofocusing should be optimized and, if 
possible, the hCG glycoform associated with PTD should be identified. Unfortunately, the 
method of chromatofocusing in its current form does not allow investigation of a specific 
hCG glycoform, since the amount of immunoreactive hCG material recovered in each pH 
fraction is too low for further (mass spectometric) analysis. Ideally, a specific sandwich-type 
assay directed against the particular hCG glycoform(s) associated with subsequent PTD 
development would be available. To increase the throughput of hCG chromatofocusing, 
however, the assay can be simplified by focusing only on the pI-interval of interest for 
PTD prediction. Measurement of a specific glycoform may give higher sensitivity. Apart 
from the presence of PTD related hCG profiles in pre-evacuation samples, specific hCG 
glycoforms may also develop after evacuation of the mole. Early prediction of PTD is 
important since less chemotherapy courses will be required and a lower number of 
patients will require comprehensive therapy for extensive metastatic disease. Diminishing 
the duration of the hCG follow-up after evacuation by earlier prediction of either PTD or 
uneventful HM will diminish patient anxiety and earlier completion of treatment will sooner 
allow another pregnancy in patients wishing to conceive. In developing countries early 
identification of PTD will most likely lead to a reduction in mortality, since currently a high 
number of patients is completely lost to follow-up after evacuation and they either die or 
return with hardly curable advanced metastatic disease [27]. Identification of patients 
eventually developing PTD around the time of evacuation enables timely treatment of 
these patients.  Further research is needed before our finding can be applied in daily 
clinical practice. 
Why do some patients with HM develop PTD while others do not?
The pathogenesis of PTD remains to be elucidated. It is unknown why some HM patients 
develop PTD, while others achieve spontaneous disease remission following evacuation. 
The most likely hypothesis is that a defect that causes PTD is already present at the time 
of uterine curettage. The possibility that PTD occurs due to incomplete uterine evacuation 
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is unlikely. With evacuation of HM at earlier gestational ages and with more widely used 
ultrasound guided curettage, no decrease in the incidence of PTD has been reported [13, 
29]. HCG levels not only correlated with the size of the tumor, which is generally known, but 
also with the prognosis of PTD in patients initially diagnosed with low-risk PTD, as shown 
in our study on resistance to single-agent chemotherapy. HCG β-subunit expression has 
been found to correlate with survival in several non-trophoblastic malignancies, such as 
bladder, lung, colon and gynaecological carcinoma [30]. HCGβ does not exhibit biological 
hCG activity, but hCG β-subunit seems to be associated with the number of tumour cells 
in epithelial carcinoma [31]. Bladder carcinoma cell numbers increased dose-dependently 
in vitro following hCGβ administration and growth stimulation was inhibited by incubation 
of cells with anti-hCGβ anti-serum. Butler et al. [32] proposed that hCG increased the cell 
number by an inhibiting effect on apoptosis. 
In a review by Iles et al. [31] ectopically expressed free hCGβ was suggested to act as an 
autocrine/paracrine growth-stimulating factor due to its potential to block tumour growth 
factor. 
Antibodies to hCGβ have shown to inhibit tumour cell growth in non-trophoblastic 
malignancies in vitro and in mice studies [33-36]. Other studies showed that hyper-
glycosylated hCG was reported to be a factor related to development of malignancy in 
GTD. In choriocarcinoma transfected mice cell growth and malignant deterioration was 
prevented by blocking the production of hyperglycosylated hCG  [37-39].  
A high risk of developing PTD may be related to the androgenetic and/or homozygous 
nature of most complete HM, since heterozygous recessive mutations in the paternal 
genome are likely to become homozygous in case of HM. This may also explain that partial 
HM is less likely to develop PTD (biparental origin) than complete moles. Women with 
biparental diploid HM (as described in several families with recurrent HM) might therefore 
be associated with a lower incidence of PTD [40]. The number of cases reported with 
biparental complete HM is too small to determine the risk for PTD accurately, but PTD did 
occur in several cases [40-52]. To our knowledge, Niemann et al. [41] were the only 
investigators  showing the effect of heterozygous versus homozygous HM on the associated 
risk of developing PTD. They found that all patients with PTD (n = 29) had a diploid 
karyotype of which 23 were homozygous, 4 were heterozygous and 2 had biparental 
chromosome sets [41]. In case PTD is as common in biparental complete HM as in other 
cases of complete HM,  abnormal imprinting might play an important role in the malignant 
deterioration, rather than paternally derived homozygous mutant alleles. Therefore, 
research on biparental diploid HM might be of great significance in unraveling the 
pathogenesis of PTD. Nearly all HM are sporadic, except for the inheritable biparental 
diploid HM [41]. Linkage to chromosome locus 19q13.4 and autosomal recessive 
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mutations at the NLRP7-gene in that region have been found in a small number of families 
with recurrent biparental diploid HM [44,47,52]. This type of HM is due to absence of 
methylation of the maternal gene (i.e. imprinting defect). In other families with recurrent 
hydatidiform mole no association with the NLRP7-gene was observed [48,50,52]. The 
mechanism for the genesis of malignant deterioration of HM remains unclear.
Can we predict resistance to single-agent chemotherapy in PTD?
Besides prediction of PTD in an early stage, it is important to detect patients with 
first-line single agent chemotherapy resistance as soon as possible. Internationally 
accepted criteria for resistance to single-agent chemotherapy are lacking, although 
most institutions use a rise or plateau in hCG levels for detection of chemotherapy 
resistance [53-56].  In 2006, Van Trommel et al. developed a serum hCG regression 
curve for prediction of MTX resistant PTD. Fifty percent of patients with MTX resistant 
PTD (n = 29) could be predicted prior to the fourth MTX course at 97.5% specificity 
[59]. Of course, this observation needed to be confirmed prior to clinical application. 
The present thesis describes an external validation study on the use of hCG cut-off 
levels for prediction of resistance to single-agent chemotherapy among patients 
treated and monitored by hCG measurement at the Trophoblastic Disease Centre 
residing at Charing Cross Hospital London. 
ROC analysis showed that at 97.5% specificity an hCG cut-off value of 737 IU/L would 
have enabled us to predict the subsequent development of single-agent chemotherapy 
resistance in 52% of patients prior to their fourth MTX course. This would have allowed 
an earlier switch to combination chemotherapy reducing the MTX exposure by an 
average of 2.5 courses. Change to combination chemotherapy should be considered 
for patients whose hCG levels exceed the hCG cut-off values Measured in blood 
collected prior to MTX course number one to five. For patients not exceeding the hCG 
cut-off levels, static or rising hCG levels should still be included in the criteria for 
change of chemotherapy. Since  each hCG  assay has its own characteristics such as 
specificity and cross-reactivity, the hCG cut-off levels presented in our validation study 
should only be used with RIA that is developed at the Charing Cross Hospital London. 
HCG cut-off levels determined for the Charing Cross RIA are ready for clinical 
implementation for prediction of single-agent chemotherapy resistance.
 
Should centralization of treatment of patients with PTD be introduced in  
the Netherlands?
Centralization of the treatment of PTD is of great significance, since the experience in 
most hospitals is very limited due to the low incidence of PTD. Moreover, PTD is a 
general discussion
128
potentially deadly disorder, with high cure rates if appropriate treatment is instituted. 
Brewer et al. showed in 1971 that treatment for GTD at the Trophoblastic Disease 
Center Chicago was associated with nine times lower morbidity and mortality than 
treatment in non-specialized institutions [60]. In a worldwide study including Dutch 
data, Kohorn et al. found that mortality in patients with GTD treated between 1995 and 
2005 was 0.4% (46 of 10,587) in those patients who were managed by physicians 
experienced in GTD management in comparison with 8.5% (99 of 1,160) in patients 
who were treated by a physician that never/occasionally treated patients with GTD 
[61]. Mortality was particularly high in post-term choriocarcinoma (11.1%) and PSTT 
(18.6%). In the United Kingdom, registration of all patients with GTD is mandatory, 
which allows centralized treatment at two referral centers (Charing Cross Hospital 
London and Weston Park Hospital Sheffield). The mortality of PTD following a complete 
HM was as low as 0.12% [61]. In the Netherlands, treatment for GTN (not for uneventful 
HM) is centrally coordinated, but not completely centralized. Most patients with 
high-risk GTN are discussed on a voluntary basis in the meetings of the Working Party 
for Trophoblastic Tumours, joined by gynaecologists, oncologists and biochemists. 
Low-risk PTD patients are generally not discussed with the Working Party. The Dutch 
Working Party for Trophoblastic Tumours merely has a coordinative and advisory 
function [62]. Between 1986 and 1997 94 patients were treated with combination 
chemotherapy, 50 patients received EMACO and for 44 patients a platinum-containing 
regimen (Hoog Brabant) was instituted. In 1986 both schedules were recommended, 
but in later years the Dutch Working Party considered EMACO as treatment of first 
choice, in accordance with international recommendations. 
Besides inconsistency in the number of consolidation courses, in thirteen of the 50 
patients treated with EMACO, the type and dosage of chemotherapeutic treatment was 
not in accordance with the Dutch guidelines [62]. The Dutch Working Party for 
Trophoblastic Tumours in association with the Working Party for Gynecologic Oncology 
of the Dutch Society for Obstetrics and Gynaecology should set up Central Specialized 
Trophoblastic Disease Centers to establish centralization of treatment. These Centers 
should cover all parts of the Netherlands and together treat all patients with low- and 
high-risk PTD and other forms of GTN to ensure a uniform treatment according to the 
worldwide guidelines for GTN management. 
In conclusion, earlier detection and evacuation of complete HM due to the introduction 
of routine first trimester ultrasound has led to earlier normalization of hCG levels. More 
research should be performed to investigate whether changing the FIGO 2000 criteria 
for PTD with respect to the aspect of time to normalisation would affect treatment 
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outcome in PTD patients. The literature and our findings clearly indicate that hCG 
follow-up in complete and partial HM can be safely discontinued after two hCG levels 
below the normal cut-off level of the assay had been achieved. In retrospect, we found 
that PTD could have been predicted by measurement of hCG glycoforms in a 
pre-evacuation serum sample in 36% of patients. This finding needs to be confirmed 
and expanded in a larger group of HM patients. The pathogenesis of PTD in HM 
remains to be elucidated. Patients with resistance to single-agent chemotherapy can 
be predicted by their hCG levels, and this method of prediction is ready for use in 
routine clinical practice in the United Kingdom. Complete centralization of treatment 
for GTN should be implemented in the Netherlands, since it has a positive association 
with enhanced treatment outcome.
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Summary
Chapter 1 provides a general introduction regarding the main subjects of the present 
thesis, including hydatidiform mole (HM), persistent trophoblastic disease (PTD) and 
human chorionic gonadotropin (hCG). HM is a non-viable form of pregnancy with 
cystic changes within the chorionic villi, most often in the absence of an embryo. HM 
can be classified as complete or partial mole and occurs in approximately 1 in 1000 
pregnancies. Following molar evacuation by uterine curettage, remaining trophoblastic 
tissue resolves spontaneously in most cases. HCG is a measure for trophoblastic 
activity. HCG follow-up after molar evacuation is essential for all HM patients to identify 
patients with PTD, a potentially deadly disorder requiring (chemotherapeutic) treatment. 
Once hCG levels below the normal cut-off level of the assay have been obtained, the 
risk of recurrent gestational trophoblastic disease (GTD) is low. PTD occurs in 
approximately 15% of all complete molar pregnancies. Less often (0.5%) partial HM 
patients develop into PTD. According to the FIGO 2000 criteria, PTD is defined as 1) a 
plateau in weekly serum hCG concentrations for 3 consecutive weeks, 2) an increase 
of the serum hCG level for 2 weeks and 3) persistence of detectable hCG levels for 
more than 6 months after evacuation. In the Netherlands, PTD is defined as a rise or 
plateau in hCG levels for 2 consecutive weeks and one or more hCG levels above the 
95th percentile hCG normogram described by Yedema et al. Markers that predict PTD 
prior to detection by the FIGO 2000 criteria currently are lacking. PTD is sensitive to 
chemotherapy, even in case of metastatic disease. In case of low-risk PTD, single-agent 
methotrexate chemotherapy (MTX) is generally instituted and patients with high-risk 
PTD receive combination chemotherapy. Seventeen to 36% of patients with low-risk 
PTD develop MTX resistance requiring change of chemotherapy. A generally accepted 
method for prediction of single-agent chemotherapy resistance is not ready for clinical 
application. 
Chapter 2 describes serum hCG regression in uneventful complete HM before and 
after the introduction of routine first-trimester ultrasonography. A group of 137 women 
with uneventful complete HM diagnosed between 1994 and 2006 was evaluated 
retrospectively and compared with a historical cohort of 106 patients with complete 
moles diagnosed between 1977 and 1989. Gestational age, preevacuation hCG 
concentration, and hCG disappearance time were significantly lower in the recent 
complete HM cohort compared with the historic series. Ninety-nine percent of the 
recent cohort achieved hCG normalization within 19 weeks after uterine evacuation 
compared with 25 weeks in the historic group. 
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Earlier serum hCG regression in the recent cohort of complete hydatidiform moles 
probably is a result of widely used first-trimester ultrasonography leading to detection 
and evacuation of complete HM at younger gestational ages, resulting in lower hCG 
levels at time of molar evacuation.
Chapter 3 concentrates on the risk of recurrent GTD in patients with complete HM who 
spontaneously achieve hCG levels below the normal cut-off level of the assay. None of the 
287 complete HM patients with completed hCG follow-up registered between 1992 and 
2001 at the Hydatidiform Mole Registry of Victoria, Australia, whose hCG levels 
spontaneously fell to normal levels subsequently developed recurrent GTD. Based on the 
literature and the current study, it seems safe to discontinue monitoring patients who attain 
normal hCG levels within 2 months after evacuation. Patients who fail to achieve normal 
hCG levels within 2 months after evacuation should be monitored with monthly hCG 
measurements for one year after normalisation to assure sustained remission.
Chapter 4 studies the risk for recurrent GTD after spontaneous normalisation of hCG 
levels in patients with HM and the risk for tumour relapse after apparent remission 
following chemotherapy in patients with low- and high-risk PTD. From 1994 until 2004, 
355 patients with HM were registered at the Dutch Central Registry of Hydatidiform 
Mole (DCRHM) and were monitored by sequential hCG measurements in serum at the 
department of Chemical Endocrinology of the Radboud University Nijmegen Medical 
Centre. Among the 355 registered hydatidiform mole patients, 265 patients attained 
spontaneous normalisation following evacuation. One patient subsequently required 
chemotherapeutic treatment for recurrent trophoblastic disease (95% confidence 
interval 0.0% to 2.1%). HCG levels did not decline to normal (<2.0 ng/mL) spontaneously 
in 90 patients; those patients subsequently received chemotherapeutic treatment. 
Relapse rates were 8.1% (6/74) and 6.3% (1/16) for the low- and high-risk category, 
respectively. Our analysis indicated that relapse risk in HM patients with spontaneous 
normalisation is extremely low (one in 265 patients) after two normal hCG levels (< 2.0 
ng/mL) are achieved. Our results support the suggestion that two subsequent normal 
hCG levels may be sufficient to ensure sustained remission after molar evacuation. In 
order to assure sustained remission, the relapse rates after chemotherapy in the 
current study emphasize the need for surveillance of PTD even after normalisation of 
hCG levels.
Chapter 5 describes the study that was performed to investigate whether the glycoform 
distribution patterns of hCG obtained by chromatofocusing in pre-evacuation serum 
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can predict development of PTD in complete HM pregnancy. Blood samples were 
collected at the Radboud University Nijmegen Medical Center from women with 
complete HM with uneventful spontaneous regression after molar evacuation (n = 32), 
from women with complete HM who developed PTD after evacuation of their mole 
(n = 28) and, as a control group, from women during the first trimester of normal 
pregnancy (n = 22). The obtained serum specimens were subjected to chromato-
focusing and hCG was determined in the fractions collected in the pI range 7.0-3.0. 
Receiver Operating Characteristics (ROC) analysis revealed that 36 % of complete HM 
patients with post-molar PTD development could have been predicted at 97 % 
specificity (pI interval 6.3-5.1, hCG cut-off 9.9%). 
Comparison of hCG percentages among complete HM with and without PTD for pH 
interval 6.3-5.1 showed p <0.0003. These findings led to the conclusion that assessment 
of the hCG glycoform profiles in pre-evacuation blood samples from patients with 
complete HM can predict future development of PTD in a proportion of patients.
Chapter 6 concentrates on the predictive value of pre-/post-evacuation serum hCG 
ratios for PTD development obtained at different intervals after molar evacuation 
compared with the current FIGO 2000 criteria for PTD. From 1977 to 2005 pre-/
postevacuation serum hCG levels were available in 69 patients with PTD registered at 
the Dutch Central Hydatidiform Mole Registry (DCRHM) residing at the Radboud 
University Nijmegen Medical Center. ROC-curve analysis was performed to calculate 
Areas Under Curves (AUCs). Sensitivity and pre/post hCG ratios were calculated at 
95% specificity. The numbers of patients predicted with PTD by pre/post hCG ratios 
versus the FIGO 2000 criteria were compared using time-specific univariate 
Kaplan-Maier curves and Cox’s regression analysis. Pre/post hCG ratios obtained in 
week 1 and 5 showed AUCs of 0.568 and 0.885 respectively, and identified 6% and 
64% of patients with PTD at 95% specificity, while with the FIGO 2000 criteria, none of 
the PTD patients could be identified in the first and 48% in the fifth week after evacuation. 
Significant differences were observed between the time of PTD diagnosis using pre/
post hCG ratios and FIGO 2000 criteria in the first 5 weeks after evacuation (mean time 
for PTD prediction, 3.8 weeks; 95% CI, 3.5-4.5 and mean time for PTD diagnosis, 4.6 
weeks; 95% CI, 4.5-4.9, respectively). Validation is required to support this 
observation.
Chapter 7 validates the previous findings of Van Trommel et al., that serum hCG levels 
facilitate early prediction of resistance to first-line single-agent chemotherapy in 
patients with low-risk PTD. Six hundred and fifty-five low-risk PTD patients who received 
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first-line MTX chemotherapy and were registered and treated between 1993 and 2007 
at Charing Cross Hospital London, United Kingdom, fulfilled the inclusion criteria. ROC 
curves were constructed to determine hCG cut-off levels and sensitivity between 
patients cured on single-agent chemotherapy (control group) and patients requiring 
change to combination chemotherapy (study group). ROC analysis identified an hCG 
cut-off value of 737 IU/L that enabled prediction of the subsequent development of 
single-agent chemotherapy resistance in 52% of patients prior to their fourth MTX 
course at 97.5% specificity. This would have enabled an earlier switch to combination 
chemotherapy reducing the MTX exposure by an average of 2.5 courses. The present 
findings confirm that serum hCG cut-off levels predict resistance to single-agent 
therapy earlier than traditional methods. Change to combination chemotherapy should 
be considered for patients whose serum hCG levels exceed these hCG cut-off values. 
For patients not exceeding the hCG cut-off levels, static or rising hCG levels should still 
be included in the criteria for change of chemotherapy. 
Chapter 8 comprises the general discussion of the thesis. Earlier detection and 
evacuation of complete HM due to the introduction of routine first trimester ultrasound 
has led to earlier normalization of hCG levels, more research should be performed to 
investigate whether advancing the FIGO 2000 criteria for PTD would affect treatment 
outcome in PTD patients. The results described in the present thesis and previous 
studies published in the literature led to the conclusion that hCG follow-up in complete 
and partial HM can be safely discontinued after two hCG levels below the normal 
cut-off level of the assay had been achieved. PTD could have been predicted by 
measurement hCG glycoform profile in a pre-evacuation serum sample in 36% of 
patients. This finding needs to be confirmed and expanded in a larger group of HM 
patients. The pathogenesis of PTD in HM remains to be elucidated. Patients with 
resistance to single-agent chemotherapy can be predicted by their hCG levels and this 
method of prediction is ready for use in routine clinical practice in the United Kingdom. 
Complete centralization of treatment for GTN should be implemented in the Netherlands, 
since it is positively associated with enhanced treatment outcome.
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Samenvatting
Mola hydatidosa is een niet-levensvatbare vorm van zwangerschap met cysteuze 
afwijkingen van het trofoblastweefsel van de placenta, over het algemeen in 
afwezigheid van een embryo. Mola hydatidosa kan worden geclassificeerd als een 
complete of partiële mola met een incidentie van circa 1 per 1000 zwangerschappen. 
Na evacuatie van de mola middels uteruscurettage gaat het resterende trofoblast-
weefsel in het merendeel van de gevallen spontaan in regressie.
Humaan choriongonadotrofine (hCG) wordt geproduceerd door de trofoblast en is 
derhalve een maat voor de activiteit van het trofoblastweefsel. Het vervolgen van 
hCG-concentraties is essentieel voor alle patiënten met molazwangerschap om 
persisterende trofoblastziekte te detecteren. Zodra normale hCG-concentraties (dat 
wil zeggen onder de afkapgrens van de hCG-assay) spontaan bereikt zijn, is het risico 
op recidief trofoblastziekte zeer laag. Volgens de criteria van de Internationale 
Federatie voor Gynaecologie en Obstetrie (FIGO) wordt persisterende trofoblastziekte 
gedefinieerd als 1) een plateauvorming van serum-hCG-concentraties gedurende 3 
weken of 2) een stijging van serum-hCG-concentraties gedurende 2 weken, of 3) 
persisteren van detecteerbare hCG-concentraties meer dan 6 maanden na evacuatie. 
In Nederland wordt persisterende trofoblastziekte gedefinieerd als een plateau-
vorming of stijging van hCG-concentraties gedurende tenminste 2 weken én een of 
meer hCG-waarden boven de 95e percentiellijn van het hCG-normogram beschreven 
door Yedema et al. Persisterende trofoblastziekte komt voor bij ongeveer 15% van alle 
complete molazwangerschappen. Minder frequent, in 0,5% van de gevallen, 
ontwikkelen patiënten met een partiële mola persisterende ziekte. Persisterende 
 trofoblastziekte is een potentieel dodelijke aandoening  die (chemotherapeutische) 
behandeling behoeft. Tumormerkstoffen om persisterende trofoblastziekte te 
voorspellen voordat een plateau of stijging van hCG-concentraties optreedt, 
ontbreken. Persisterende trofoblastziekte is gevoelig voor chemotherapie, zelfs in het 
geval van gemetastaseerde ziekte. In geval van laagrisico-trofoblastziekte, wordt 
gestart met methotrexaatmonochemotherapie. In geval van hoogrisico-persisterende 
trofoblastziekte wordt combinatiechemotherapie gegeven. Zeventien tot 36% van de 
patiënten met laag-risico-persisterende trofoblastziekte ontwikkelen methotrexaatre-
sistentie en behoeven behandeling met andere chemotherapeutica. Een algemeen 
geaccepteerde methode om methotrexaatresistentie te voorspellen is nog niet 
beschikbaar voor toepassing in de dagelijkse praktijk. 
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Sinds de introductie van routine-eerstetrimesterechoscopie wordt mola hydatidosa in 
een vroeger stadium van de zwangerschap gediagnosticeerd. In de retrospectieve 
studie beschreven in Hoofdstuk 2 werden 137 patiënten met complete mola 
 gediagnosticeerd tussen 1994 en 2006 (na de introductie van routine-eerstetrimester-
echoscopie) vergeleken met een historisch cohort van 106 patiënten met complete 
mola gediagnosticeerd tussen 1977 en 1989 (voor de introductie van routine-eerste-
trimesterechoscopie). Zwangerschapsduur en preëvacuatie hCG-concentraties waren 
significant lager en de hCG-verdwijningstijd significant korter in het meest recente 
cohort. De kortere hCG-verdwijningstijd in het recente cohort is meest waarschijnlijk 
het gevolg van de introductie van routine-eerstetrimesterechoscopie, leidend tot 
vroegere detectie en evacuatie van complete molazwangerschappen, resulterend in 
lagere hCG-concentraties ten tijde van de evacuatie van het molaweefsel.
De kans op recidief trofoblastziekte bij patiënten met spontane hCG-normalisatie na 
evacuatie van mola hydatidosa is zeer laag. Geen van de 287 complete mola patiënten 
geregistreerd in de Mola Hydatidosa Registratie in Victoria, Australië (1992-2001) 
ontwikkelden recidief-trofoblastziekte na spontane hCG-normalisatie. Gebaseerd op 
de literatuur en Hoofdstuk 3 van het huidige proefschrift kan geconcludeerd worden 
dat bij patiënten die binnen twee maanden na mola-evacuatie normale hCG-waarden 
bereiken, de hCG-controles na twee normale waarden gestaakt kan worden. 
Daarentegen, op basis van literatuurgegevens dient bij patiënten die pas na meer dan 
twee maanden na evacuatie normale hCG-waarden bereiken, gedurende een jaar na 
normalisatie maandelijks bepaling van  hCG plaats te vinden.
In Hoofdstuk 4 wordt het risico op recidief trofoblastziekte na spontane normalisatie 
van hCG-concentraties bij patiënten met mola hydatidosa en de kans op recidief na 
hCG-normalisatie bij patiënten met laag- en hoogrisico persisterende ziekte 
beschreven. Tussen 1994 en 2004 werden 355 patiënten met mola hydatidosa 
geregistreerd bij de Centrale Molaregistratie Nederland en gecontroleerd middels 
hCG-bepalingen. Bij 265 van de 355 patiënten trad spontane hCG-normalisatie op. 
Bij één van deze 265 patiënten trad recidief trofoblastziekte op (95% betrouwbaar-
heidsinterval: 0,0 tot 2,1%). Negentig patiënten ontwikkelden persisterende trofo-
blastziekte en werden behandeld met chemotherapie. Recidief na persisterende 
 trofoblastziekte trad op bij 6 van de 74 patiënten (8,1%) met laagrisico-persisterende 
trofoblastziekte en 1 van de 16 patiënten (6,3%) met hoogrisico-persisterende trofo-
blastziekte. Het risico op recidief trofoblastziekte na spontane hCG-normalisatie is 
zeer laag (1/265).Deze resultaten bevestigen dat twee normale hCG waarden 
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voldoende zijn om te spreken van remissie. Aangezien het risico op recidief trofo-
blastziekte na persisterende trofoblastziekte aanzienlijk is, blijft controle middels 
maandelijkse hCG-bepalingen na hCG-normalisatie voor deze groep patiënten echter 
aangewezen.  
Momenteel zijn er geen tumormerkstoffen beschikbaar om het ontstaan van 
persisterende trofoblastziekte voorafgaand aan evacuatie van het molaweefsel te 
voorspellen. In Hoofdstuk 5 wordt de studie naar het voorkomen van hCG glyco-
vormprofielen in preëvacuatieserum van complete molapatiënten met en zonder 
persisterende trofoblastziekte beschreven. Van 32 vrouwen met complete mola en 
spontane normalisatie, 28 vrouwen met complete mola gevolgd door persisterende 
trofoblastziekte en 22 vrouwen met een ongecompliceerde zwangerschap (eerstetri-
mester, controlegroep) was voldoende serum beschikbaar voor analyse. Er vond 
chromatofocusing plaats en hCG-concentraties werden bepaald in alle fracties van 
het pH-interval 7,0-3,0. Uit analyse met behulp van receiver operating characteristics 
(ROC) curves bleek dat in retrospect in 36% van de complete molapatiënten die later 
persisterende trofoblastziekte ontwikkelden reeds in preëvacuatieserum persisterende 
trofoblastziekte te detecteren zou zijn geweest (97% specificiteit, pH-interval 6,3-5,1, 
afkapwaarde 9,9%, p < 0,0003). HCG-glycovormprofielen blijken voor een deel van 
de patiënten een voorspellende waarde te hebben voor het ontwikkelen van 
persisterende trofoblastziekte.Nader onderzoek is vereist om deze resultaten te 
bevestigen dan wel uit te breiden.
In Hoofdstuk 6 wordt de voorspellende waarde van pre-/postevacuatie serum-hCG-
ratio’s voor het ontwikkelen van persisterende trofoblastziekte vergeleken met de 
FIGO 2000-criteria voor persisterende trofoblastziekte. Voor 69 patiënten waren in de 
periode van 1977 tot 2005 pre- en postevacuatie-hCG-waarden beschikbaar in de 
Centrale Molaregistratie Nederland in het UMC St Radboud Nijmegen. Sensitiviteit en 
pre-/post-hCG-ratio’s werden berekend bij 95% specificiteit met ROC-curve analyse. 
Pre-/post-hCG–ratio’s verkregen in week 1 en 5 na evacuatie identificeerden respec-
tievelijk 6% en 64% van de patiënten met persisterende trofoblastziekte bij een 
specificiteit van 95%. Met de FIGO 2000-criteria werden geen patiënten  geïdentificeerd 
in de eerste week en 48% in de vijfde week na evacuatie. Validatie van dit onderzoek 
is vereist om deze resultaten te ondersteunen.
Er zijn momenteel geen wereldwijd geaccepteerde criteria beschikbaar voor het diag-
nosticeren van monochemotherapieresistentie bij laagrisico-persisterende trofoblast-
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ziekte. Over het algemeen wordt bij stijging of plateauvorming van hCG-concentraties 
besloten over te gaan tot combinatie-chemotherapie. In Hoofdstuk 7 worden de 
bevindingen uit de studie van Van Trommel et al. naar serum-hCG-afkapwaarden voor 
het voorspellen van monochemotherapieresistentie gevalideerd. Zeshonderdvijfen-
vijftig patiënten met laagrisico-persisterende trofoblastziekte werden tussen 1993 en 
2007 behandeld met eerstelijnsmethotrexaat in het Charing Cross Hospital in Londen, 
Groot-Brittannië. HCG-concentraties van patiënten die in remissie gingen na 
behandeling met monochemotherapie (controlegroep) werden vergeleken met hCG- 
waarden van patiënten die combinatiechemotherapie nodig hadden (studiegroep). 
Met behulp van ROC-curve-analyse werden hCG-afkapwaarden verkregen. Voorafgaand 
aan de 4e methotrexaatkuur kan 52% van de patiënten met monochemotherapie-
resistentie voorspeld worden met een specificiteit van 97,5%. Dit zou in theorie geleid 
hebben tot een daling van gemiddeld 2,5 methotrexaatkuren. De huidige bevindingen 
bevestigen dat bij gebruik van serum-hCG-afkapwaarden monochemotherapieresis-
tentie eerder  opgespoord kan worden dan met plateauvorming of stijging van het hCG. 
Indien de afkapwaarden overschreden worden, moet verandering naar combinatie chemo 
-therapie worden overwogen. Indien hCG-concentraties onder de afkapwaarden blijven, 
dient het overstappen naar combinatie-chemotherapie vooralsnog te geschieden op 
basis van  plateauvorming of stijging van de hCG-concentraties.
Hoofdstuk 8 vormt de algemene discussie van het proefschrift. Vroegere detectie en 
evacuatie van complete mola na de introductie van routine-eerstetrimesterechografie 
heeft geleid tot vroegere normalisatie van hCG-concentraties. Er dient meer onderzoek 
verricht te worden naar de implicaties van deze bevinding op de FIGO 2000-criteria. 
De resultaten uit voorgaande onderzoeken en het huidige proefschrift hebben geleid 
tot de conclusie dat hCG-follow-up bij complete en partiële molazwangerschappen 
veilig kan worden gestaakt nadat twee normale hCG-waarden zijn bereikt. 
persisterende trofoblastziekte kan in 36% van de gevallen reeds voorafgaand aan 
evacuatie voorspeld worden door middel van hCG-glycovorm-profielen. Deze 
bevinding dient nog bevestigd te worden in grotere aantallen patiënten. Er is weinig 
bekend over de pathogenese van persisterende trofoblastziekte na mola hydatidosa, 
dit dient dan ook in de toekomst nader onderzocht te worden. Patiënten met resistentie 
tegen monochemotherapie kunnen in een vroeger stadium opgespoord worden op 
basis van hCG-afkapwaarden; deze methode is geschikt voor toepassing in de 
klinische praktijk in Groot-Brittannië. De behandeling van trofoblasttumoren dient 
volledig gecentraliseerd te worden, aangezien dit positief geassocieerd is met een 
gunstige uitkomst van de behandeling.
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